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Nederlandse samenvatting
–Summary in Dutch–
Massaal parallel sequentioneringstechnieken zijn veelbelovend voor het in kaart
brengen van virale populaties in bijvoorbeeld HIV-1 en HCV geïnfecteerde pa-
tienten. De analyse van deze virale populaties kan ons inzicht geven in de ontwik-
keling van resistentie hetgeen in een volgend stadium behandeling kan verbeteren.
Standaard genotypering levert enkel informatie over de meest voorkomende virale
varianten in de populatie. Massaal parallel sequentioneringstechnieken daarente-
gen laten toe om ook de laag frequente varianten te typeren. De pyrosequencing
techniek, gecommercialliseerd door Roche werd tot voor kort het meest gebruikt
voor de detectie van deze laag frequente varianten. Maar de MPS-techniek ontwik-
keld door Illumina is aan een opmars bezig en heeft het grote voordeel een gro-
tere sequentioneringsdiepte te bereiken voor dezelfde kostprijs. Bovendien heeft
Roche recent aangekondigd dat ze de pyrosequencing techniek niet verdere on-
dersteunen. Daarom bestudeerden we in eerste instantie of Illumina’s techniek
inderdaad geschikt is voor de karakterisatie van genetische variabiliteit binnen vi-
rale populaties en of de 1% rapporteringstechniek, die gebruikelijk is voor 454,
ook toegepast kan worden. We kunnen concluderen dat varianten aanwezig in de
populatie met een frequentie tot 1% accuraat gedetecteerd kunnen worden.
Eén van de grootste uitdagingen in de detectie van laag frequente varianten zijn
de fouten geïncorporeerd tijdens het sequentioneringsproces. Het onderscheiden
van fouten van laag frequente varianten wordt bemoeilijkt doordat beiden kunnen
voorkomen aan vergelijkbare frequenties. Vermits deze fouten technologisch niet
vermeden kunnen worden, moeten we op zoek gaan naar statistische algoritmes die
helpen bij het differentiëren. Idealiter willen we varianten detecteren met frequen-
ties ver onder de 1%. Dit zou ons toelaten om de klinische relevantie van de laag
frequente varianten te bestuderen in de context van verschillende anti-retrovirale
behandelingsregimes. Twee verschillende wegen werden bewandeld om dit doel
te bewerkstelligen.
In eerste instantie werden de kwaliteitsscores, meegeleverd door Illumina tij-
dens het sequentioneringsproces, gebruikt als filteringscriterium om het aantal vals
positieven terug te dringen. De grenswaarde voor de kwaliteitsscores, waaronder
we de variant beschouwen als fout, wordt bepaald aan de hand van getrunceerde
normale mixture distributies gefit op de kwaliteitsscores. Toepassing van deze
methode op zowel klinische stalen als plasmides leert ons dat we het aantal vals
positieven inderdaad kunnen terugsschroeven vooral in GC-rijke gebieden, waar
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Illumina meer dan een gemiddeld aantal fouten maakt. De 1% rapporteringslimiet
kon echter nauwelijks naar beneden gebracht worden.
Uit de literatuur en eigen experimenten leerden we dat de kwaliteitsscores niet
altijd de echte error probabiliteit weergeven. Vaak zijn deze een onderschatting.
Daarom modelleren we de error probabiliteiten van de beste en tweede beste base
calls in functie van de kwaliteitsscores. Deze probabiliteiten geven aan of een
bepaalde read afkomstig is van een gegeven cluster. De virale populatie kan bij-
gevolg afgeleid worden van de cluster centers en de grootte van de cluster. Deze
methode laat toe om laag frequente varianten te detecteren waarbij we ver onder
de 1% duiken zonder aan specificiteit in te boeten.
Dit doctoraatsprogramma getiteld "detectie van laag frequente varianten in vi-
rale populaties gebruik makend van massaal parallel sequentioneringsdata"werd
positief beoordeeld door het IWT (Baekeland mandaat 100679) en ging van start
op 1 januari 2011. Het project is uitgevoerd in nauwe samenwerking tussen Jans-
sen Pharmaceutica en Universiteit Gent.
English summary
In a virology research environment, massive parallel sequencing technology has
great opportunity to study viral quasispecies in HIV-1 and HCV-infected patients,
which is essential for understanding pathways to resistance and can substantially
improve treatment. Whereas standard genotyping only provides information on
the most abundant sequence variants, the massively parallel sequencing technolo-
gies allow in-depth characterization of sequence variation in more complex pop-
ulations, including low-frequency viral strains. Until recently, pyrosequencing
platforms, commercialized by Roche, have been the most popular for detection
of low-level drug resistant variants. However, current short-read sequencing tech-
nologies, like the Illumina’s sequencing-by-synthesis platform, have the advantage
of providing a higher sequencing depth at a lower cost per sequenced base. Ad-
ditionally, Roche recently announced that they will fade out the pyrosequencing
technique by mid-2016. Hence, we investigated the feasibility of using Illumina’s
GAIIx to characterize genetic variability in viral populations where the key ques-
tion was to achieve the same widely accepted lower limit of detection of 1% as in
454. We conclude that variants down to a frequency of 1% could be detected with
a great accuracy using Illumina’s sequencing platform at a lower cost.
One of the challenges in the detection of low-frequency viral strains concerns
the errors introduced during the sequencing process. Technology-associated errors
may occur up to equal or even higher frequencies than the truly present mutations,
impeding a powerful assessment of low-frequency virus mutations. As there are
no obvious solutions to reduce the technical noise by further improvements of the
technology, we believe that the search for statistical algorithms that can better cor-
rect the technical noise can be pivotal. This has the potential to enable sequencing
at a much deeper level, far below the 1% level. Having the desired algorithm
at hand we could investigate the relevance of minor mutations in the context of
different antiretroviral therapy regimens because they might help in defining the
clinical benefit of low-frequency resistance testing. Two different approaches to
differentiate technical noise from low-frequency variants were investigated.
At first, we used the sequencing quality scores of Illumina as filtering criteria
to reduce the number of false findings during variant calling. These quality scores
reflect the probability of an error during sequencing. Instead of applying hard
thresholds, which are often too stringent or too relaxed, we developed an adaptive
thresholding method based on fitting truncated mixture distributions on the quality
scores. With this approach we could reduce the number of false-positive findings,
especially in GC-rich regions which are known to be error prone. However, the
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1% limit of detection could only partially be lowered.
From literature and own experiments, we know that the quality scores do not
always reflect the true error probabilities. Often they are underestimated. There-
fore in our second approach we modeled the error probabilities of the best and
second best base calls as a function of the quality scores. These probabilities ex-
press if a given read was generated by a given cluster. The viral population can be
inferred from the cluster centers and the cluster sizes. This approach reduces the
number of false-positive findings drastically and allows us to lower the 1% limit
of detection without losing the specificity.
This doctoral research program "low-frequency variant detection in viral popu-
lations using massively parallel sequencing data" was granted by IWT (Baekeland
mandatory 100679) and was performed in close collaboration between Janssen
Pharamaceuticals and Ghent University.
1
Introduction
Virology is the study of viruses, infectious agents that reproduce inside the cells of
living hosts. Viruses consists of genetic material made from either DNA or RNA
which are surrounded by a protective coat. They depend on host cells that they in-
fect to reproduce and they can infect all types of life forms, from animals and plants
to bacteria. Since Dmitri Ivanovsky’s 1892 article [1] describing a non-bacterial
pathogen infecting tobacco plants, viruses are found to be the most abundant bi-
ological entities on the planet, most of which infect microorganisms [2]. Recent
studies estimated that there is a minimum of 320,000 viruses in mammals [3]. One
motivation to study these viruses is the fact that they can cause many infectious
diseases. Most viral infections, however, are short-lived and of little consequence
to the host. Among the reasons for this is the development of a defense system
in the host to inhibit viral replication and to destroy virally infected cells in the
body [4]. As these systems have developed in their hosts, viruses have needed to
modify themselves in order to evade or subvert this immune response. The host
immune response is a very complex interwoven series of chemical and cellular
interactions that combine to attempt to eliminate viruses from the body. While
it is not surprising that viruses have had to develop strategies to overcome host
defenses, the number of adaptations and the complexities of these adaptations is
remarkable. Adaptations of some viruses are so successful that they are able to
escape from these immune responses and can cause severe chronic infections, like
for instance Human immunodeficiency virus (HIV) and hepatitis C (HCV) [5, 6].
HCV infects cells in the liver called hepatocytes which triggers the human im-
mune system and leads to inflammation. However, due to the chronic infection,
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these prolonged inflammations cause scarring and extensive scarring in the liver is
called cirrhosis. When the liver becomes cirrhotic, it fails to perform its normal
functions and this leads to serious complications and even death. HIV on the other
hand is able to weaken the immune system itself by destroying important cells,
called T-cells or CD4-cells that fight disease and infection. Over time, HIV can
destroy so many of these cells that your body can’t fight infections and diseases
anymore. When that happens, HIV infection can lead to AIDS, the final stage of
HIV infection. Patients having AIDS are getting infections or cancers that rarely
occur in healthy people, because of the damage of their immune system and these
infections can be deadly. It is clear that both diseases represent a significant global
health threat [7]. HIV and HCV affect millions of humans worldwide, with esti-
mates of 35 million people living with HIV at the end of 2013 and 150 million
people with chronic hepatitis C infection. Each year 1.5 million people die from
HIV-related causes globally, while 350,000 to 500,000 people die each year from
HCV-related liver diseases.
1.1 Viral dynamics
During the viral life cycle, a virus enters the host cell by binding to its receptor,
uncoats, make replicates of its own DNA or RNA and proteins using polymerases
(see text box for more background information), and then reassembles to form
new virus particles which are subsequently released into the host system (Figure
1.1). When viruses infect host cells they provide some of their own molecular
equipment such as DNA/RNA polymerases and proteases to enable replication.
However, this still requires that, as soon as the cell is invaded, the virus hijack
the host cell machinery to manipulate cellular proteins in order to do their replica-
tion. Host cells are forced in this way to produce many thousands of copies of the
original virus at an extraordinary rate. For HIV and HCV, the number of copies
can reach 1011 to 1012 per infected individual per day. However, these replica-
tions are error-prone, resulting in high mutation rates. Especially RNA-viruses,
like HIV and HCV with RNA as genetic material have high mutation rates which
is attributed partly to the absence of a proof-reading repair activity in the RNA
polymerases in contrast to the DNA polymerases [8, 9] during their replication.
These high mutation rates together with short generation times result in a constant
production of genetic variants. Consequently, RNA viruses exist in their host as
complex populations composed of several closely related subgroups, which are re-
ferred to as viral quasi-species (Figure 1.2) [10–12]. This heterogeneous mixture
of genomes allows a viral population to rapidly adapt to changing environments;
for example after infecting a new host with a different immune response [13] or
while being exposed to different drugs [14–17].
Antiviral drugs are developed to target specific parts within the viral life cycle.
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Figure 1.1: General view on the viral life cycle. During the viral life cycle, viruses bind to
their receptor, enter the host cell, uncoats, build copies of their genetic material and
assemble. At the end copies of virus are released to the host system.
Because viruses use the host’s cells to replicate, it is very difficult to find targets
for the drug that would interfere with the virus without also harming the host or-
ganism’s cells. Hence, often the targets are proteins that are translated from the
viral genome. However, viral variation imposes a clear challenge here. Viruses
carrying mutations in parts of the viral genome which translate to the drug-targets
might develop resistance to the antiviral drugs and will out compete other viral
variants. This is of course an important threat in the treatment of patients where
drug resistance variants are present within the viral population. According to epi-
demiological studies in Europe and the USA, 8% to 11% of antiretroviral naive
patients, patients that have never been treated with relevant drugs against HIV, are
infected with a virus harboring drug resistance variants [18]. Therefor, therapeutic
guidelines suggest that treatment management at baseline can be improved by a
more detailed characterization of sequence variation within the viral population
present in a patient. The standard of care for HIV patients for instance is a com-
bination therapy with 2 to 3 different classes of antiretroviral drugs, attacking the
viruses in different stages of their viral life cycle. If a person’s strain of HIV is
resistant to a certain class of drug, taking that type of drug may be ineffective or at
worse, harmful as it may lead to failure of the treatment. Hence this type of drug
should be avoided in the combination therapy. Not only at the start of the treat-
ment, but also during the treatment, sequence variation should be investigated. As
a result of poor adherence, interruptions in treatment and the use of ineffective
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Figure 1.2: Evolution of viral quasispecies. During replication mutations are incorporated
in the genomes, resulting in a viral population consisting of closely related subgroups.
Viral genomes are represented as horizontal lines and mutations as different colored
symbols on the lines. Discontinuous lines indicate genomes that have acquired deleterious
mutations, indicated as a green star. These variants cannot survive. (adapted from
http://mmbr.asm.org/content/76/2/159/F5.expansion.html )
drugs or faulty drug combinations, HIV can acquire resistance associated muta-
tions during treatment. When the resistance develops, usually the drug regimen
needs to be changed.
The pre-existence of these variants, prior to treatment, can be caused as said
by the continuous input of new genomic sequences during the replication or is
transmitted during infection. It can be predicted that all possible mutations nat-
urally occur at a frequency of ≈ 0.01% [19] since the polymerases, involved in
the replication, make one error in 104 to 105 nucleotides. Therefore, only those
variants that occur at higher frequencies are likely to be able to out compete the
other variants to develop resistance. A recent study suggest that low-frequency re-
sistant variants in HIV [20] are only clinically meaningful when present above 1%
in the viral population. However, it remains a debated issue whether the presence
of minority sub-populations that decrease the sensitivity to anti(retro)viral agents
influence the treatment outcome or not and which low-frequencies are still clini-
cally relevant. According to some studies, low-frequency baseline drug resistance
is associated with a higher risk of treatment failure [14–16]. Other studies have not
found an influence of minority resistance mutations on the treatment response [21].
Currently, in clinical practice the determination of the variants within the viral
population, called genotyping is done by Sanger sequencing [22]. Sanger sequenc-
ing can only detect viral variants representing more than 15 to 25% of the viral
population. Although, genotyping can be performed through a variety of different
methods, sequencing has the added value that no prior knowledge of the variants
is needed. Massively parallel sequencing (MPS) technologies allow a in-depth
characterization of viral populations, including low-frequency viral strains [23].
INTRODUCTION 1-5
Central dogma of molecular biology.
Figure 1.3: a) Flow of the genetic information within a biological system from DNA
replication, transcription of DNA to RNA and translation of RNA to proteins. b)
Translation of genetic information to protein level is done by nucleotide triplets
which code for the different amino acids. c) The genetic code of the 64 (43) possible
codons and their corresponding amino acids. ( source
http://en.wikipedia.org/wiki/File:Translation-genetics.png )
The central dogma is an explanation of the flow of genetic information
within a biological system [24] (Figure 1.3a). The general transfers consist
of (1) DNA replication, (2) transcription of DNA to RNA, and (3) translation
of RNA to proteins. (1) Deoxyribonucleic acid (DNA) is a molecule that en-
codes the genetic instructions used in the development and functioning of all
known living organisms and some viruses. Most DNA molecules consists of
two complementary nucleic acid strands coiled around each other to form a
double helix [25]. The DNA strands are composed of simpler units called nu-
cleotides - guanine (G), adenine (A), thymine (T) or cytosine (C). According
to nucleotide pairing rules (A with T and C with G), hydrogen bonds bind the
nitrogenous bases of the two separate polynucleotide strands to make double-
stranded DNA. Each strand of the original DNA molecule serves as template
for the production of the complementary strand during replication. A num-
ber of proteins are associated with the replication which helps in terms of the
initiation and continuation of DNA synthesis. Most prominently, DNA poly-
merase synthesizes the new DNA by adding complementary nucleotides to the
template strand. (2) In the next step of the flow, the genetic information hard
wired into DNA is transcribed into individual transportable cassettes, com-
posed of messenger RNA (mRNA). Thereto RNA polymerases adds com-
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plementary RNA nucleotides to subunits of the DNA strands. Each mRNA
cassette contains the program for synthesis of a particular protein (or small
number of proteins). (3) The basic process of protein production is addition
of one amino acid at a time to the end of a protein (Figure 1.3b). This oper-
ation is performed by a ribosome. The choice of amino acid type to add is
determined by the mRNA molecule. Each amino acid added is matched to a
three nucleotide subsequence of the mRNA, called a codon.
This dogma that evolved in 1950s and 1960s was contradicted in 1970 by
the discovery of enzymes called reverse transcriptase. This enzyme uses a
RNA template to catalyze the synthesis of DNA which is the reverse of the
transcription step in the central dogma. These enzymes are encoded and used
by reverse-transcribing viruses, such as HIV. These viruses transcribe their
RNA genomes into DNA which is then integrated into the host genome and
replicated along with it. Reverse transcriptases exhibit high error rates intro-
ducing errors at frequencies of one per 1,500 to 30,000 nucleotides during the
DNA synthesis and contribute as well to viral diversity.
1.2 Massively parallel sequencing
Massively parallel sequencing encompasses several high-throughput approaches to
DNA sequencing where the precise order of nucleotides within a DNA molecule is
determined; it is also referred to as next-generation sequencing (NGS) [26]. MPS
platforms differ in engineering configurations and sequencing chemistry. They
share, however the technical paradigm of sequencing by synthesis mostly for mul-
tiple DNA-sequences at the same time. The general workflow to investigate the
genetic make up of the virus with MPS is displayed in Figure 1.4 and explained in
the subsequent sections.
1.2.1 Library preparation
The library of DNA sequences representing the viral population need to be gener-
ated prior to the sequencing. For RNA viruses the viral RNA needs to be converted
to DNA. Viral RNA is extracted from plasma samples collected from patients and
reverse transcribed. The resulting complementary DNA (cDNA) is used as start-
ing material for the amplification of the drug target region on the viral genome of
interest using PCR, a polymerase chain reaction [27]. This is followed by a fur-
ther enrichment of the region of interest using PCR. PCR is based on the ability of
DNA polymerases to replicate DNA fragments (see text box). These polymerases
are error-prone similar to the RNA polymerases in the viral replication, but to
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Figure 1.4: The subsequent steps in the massively parallel sequencing process for
inferring viral populations are: library preparation, sequencing-by-synthesis,
demultiplexing, alignment and variant calling
lesser extent [28]. In addition, the relative frequencies of viral variants can be dis-
turbed by selective amplification bias, especially in low viral load isolates. The
DNA sequences containing the drug target region are subsequently fragmented to
DNA fragments of a certain length dependent on the MPS platform. The library of
these DNA fragments, representing the viral population for a specific drug target,
is ready to be sequenced by synthesis. Once these DNA fragments are sequenced
they are called reads.
The total number of reads(N), together with the length of these reads (L) and
the length of the target region of interest (R) defines the depth (C) of the sequencing
process [C = LN/R]. The depth, also called coverage, is the average number of
reads that represent a given nucleotide position of the viral genome. Sufficient
coverage is needed to be able to detect the low frequency variants.
1.2.2 Sequencing-by-synthesis
Sequencing-by-synthesis involves taking a single strand of the DNA fragments to
be sequenced and then synthesizing its complementary strand enzymatically. Two
different approaches are explained in the following sections.
1.2.2.1 Pyrosequencing
Pyrosequencing platforms, massively parallel sequencing technology commercial-
ized by RocheTM [29], have been the most popular for detection of low-level drug-
resistant variants due to their ability to produce long read lengths [30] up to 400
bp. The sequencing is conducted as follows: DNA fragments, representing the vi-
ral population, are attached to beads in conditions that favor one fragment per bead.
The beads are captured into separate emulsion droplets and PCR amplification oc-
curs within each droplet resulting in beads covered with about 10 million clonal
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Figure 1.5: In each cycle of the pyrosequencing reaction, one of the four nucleotides is
present. Incorporation of the nucleotide in the DNA strand results in the release of PPi
that converts APS to ATP. ATP reacts with luciferin to produce light which is captured by
lasers. Extrapolation of the intensity signal reveals the number of nucleotides that is build
in at this cycle. ( source www.454.com )
copies of a single DNA fragment [31]. Each clonally amplified bead is transferred
into a single well of a PicoTiterPlateTM. All beads are sequenced-by-synthesis si-
multaneously using a pyrosequencing reaction [32]. A pyrosequencing reaction
consist in the cyclic flowing of nucleotide reagents where the repeated flow se-
quence is T, A, C and G. At each cycle one of the four nucleotides is delivered to
the wells in sufficient amounts. Incorporation of a nucleotide (or more than one of
the same letter) in the DNA strand results in the release of inorganic pyrophospate
(PPi) that converts adenosine 5′ phosphosulfate (APS) to adenosine triphospate
(ATP) which react with luciferin to produce oxyluciferin and light (Figure 1.5).
The signal intensity at each nucleotide flow, for a particular well, is a proxy for
the number of nucleotides - if any - that is incorporated. Quality scores are also
derived from these intensities and reflect the probability that the called nucleotide
is not an overcall. After each cycle, the excess of nucleotides is washed away, and
the next nucleotide in the flow is added. At the end of the sequencing process,
reads are obtained for each of the beads containing the nucleotides incorporated
over all cycles together with the quality scores for each nucleotide.
The pyrosequencing approach is prone to errors that result from either carry
forward errors or incomplete extensions (CAFIE). In the latter case, some DNA
fragments on a bead fail to incorporate the nucleotide during the appropriate base
flow. These fragments that fail must wait another flow of the other nucleotides be-
fore they can continue to sequence and thus those fragments will incorporate out-
of-phase with the rest of the fragments. Carry forward errors on the other hand
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Figure 1.6: Density estimates of the log2 transformed intensities for different cycle
numbers and separated per nucleotide. Cycle number 5, for instance, corresponds with the
fifth cycle where the nucleotides T, A, C and G were consecutively added. A clear
bimodality can be observed corresponding to background and incorporation signal of a
particular nucleotide. This bimodality becomes less apparent with increasing cycle
number due to phasing [34].
occur when a trace amount of nucleotide remains in a well after the wash, per-
petuating premature nucleotide incorporation for specific sequence combinations
during the next nucleotide flow. Again it causes those fragments to incorporate
nucleotides out-of-phase with the remaining fragments on the bead [33]. These
errors accumulate as the sequencing process progresses and near the end more
fragments are out of phase. Hence, the difference between background and incor-
poration signal becomes less apparent with increasing cycle number (Figure 1.6).
Additionally the extrapolation of the intensity signal to the number of nucleotides
becomes more problematic resulting in homopolymer length inaccuracies in the
final sequence.
1.2.2.2 Illumina sequencing technology
Short-read sequencing technology, commercialized by IlluminaTM has gradually
increased its read lengths [35]. This in combination with a higher sequencing
depth at a lower cost per sequenced base makes them an attractive alternative in
viral population sequencing. The announcement by Roche to fade out their tech-
nology by mid-2016, illustrates the pressing need to focus on alternative technolo-
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gies. The performance characteristics of IlluminaTM for the characterization of
sequence variation in viral population is assessed in the following chapter. The
sequencing itself is conducted with the following steps. DNA fragments are spa-
tially segregated on the surface of a glass slide, called flow cell, which consists of
8 lanes for the Genome Analyzer II (one of Illumina’s sequencing devices). The
DNA fragments are extended to create copies through a series of bridge ampli-
fications resulting in millions of unique clusters (Figure 1.7) [36]. The spatially
segregated clusters on the flow cell are sequenced-by-synthesis simultaneously.
The complementary DNA strands of the fragments are build up one base at the
time making use of fluorescently labeled, reverse terminated nucleotides. Natural
competition minimizes incorporation bias since all four reversible terminated nu-
cleotides (dNTPs) are present during each sequencing cycle. After each cycle, the
flow cell is imaged in a series of non-overlapping regions, called tiles. The clusters
within these tiles, while being excited by laser, generate a quadruplet of intensities,
one channel for each nucleotide type. The highest intensity of the four channels
determines the nucleotide that is actually incorporated in that cycle. A quality
score is derived from each quadruplet of intensities and expresses the probability
of calling the wrong nucleotide. The stronger the signal in one of the quadruplets,
the higher the probability that it is a correct call. Before the next cycle is started,
the fluorescently labeled reversible terminator is cleaved to allow incorporation
of the next nucleotide. At the end of the sequencing process, reads with the nu-
cleotide sequences are obtained for each of the clusters together with the quality
scores for each base.
Many of the steps of the sequencing process are again error-prone [37]. Over-
lapping emission spectra of the fluorophores and loss of synchrony of the sequence
copies within a cluster can reduce the intensity of the signals which may hamper
the correct interpretation of the intensities and which may result in incorrect as-
signment of bases. The loss of synchrony, similar to 454, introduces particularly
errors towards the end of the reads. The marginal distributions for the 4 different
bases at three different cycles in the sequencing process are shown in Figure 1.8.
It is clear that the incorporation signal of a particular base diminishes towards the
end of the reads.
Both the base calls and the quality scores obtained after sequencing are stored
in a text-based format, called FASTQ format which normally consist of four lines
per sequence [38]. Line 1 begins with a @ character, followed by a sequence iden-
tifier which provides the coordinates (lane, tile, x and y-coordinates) of the cluster
on the flow cell. Line 2 is the sequence itself. Line 3 begins with a + character
and is optionally followed by the same sequence identifier as in line 1. Line 4 rep-
resent the quality scores, which are ASCII encoded + 33. This line must contain
the same number of symbols as letters in the sequence of line 2. An example is the
following:
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Figure 1.7: Sequencing-by-Synthesis using Illumina’s technology. Cluster growth: DNA
fragments are copied through a series of bridge amplifications resulting in unique clusters
spatially segregated on the flowcell. Sequencing: Each DNA strand is sequenced by
synthesis one base at the time (cycle) using fluorescently labeled nucleotides. Image
acquisition: After each round of synthesis, clusters are excited by laser emitting the color
that identifies the newly added base. Base calling: At the end of the process, reads are
obtained containing the bases incorporated in each cycle. (source
http://openwetware.org/wiki/BioMicroCenter:Sequencing )
@ HWUSI-EAS1524:12:FC:1:1:18845:1091 1:N:0:
ATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCC
+
IIIIIIIIIIIIIIIIIIIHIIIIIIIIIIIIIIIIIIIHIIHIHIHFGHF
1.2.3 Demultiplexing and alignment
As massively parallel sequencing are high throughput approaches, several samples
can be loaded simultaneously on the PicoTiterPlateTM or on the flow cell for 454
and Illumina respectively. Thereto, the DNA fragments are flanked by sample-
specific adapters prior to the sequencing which allows demultiplexing after the
sequencing process. After sequencing and demultiplexing, fastq files are obtained
for each sample which contains the sequences of the DNA fragments representing
the whole viral population. Since, the viral genome was fragmented prior to the
sequencing one needs to figure out the corresponding genomic region of each read,
a process which is called alignment. The development of alignment algorithms has
been successful and many short-read aligners are available to be included in the
data analysis pipeline [39].
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Figure 1.8: Marginal distributions of the intensities for each of the four channels
representing one of the 4 nucleotides, for three different positions in the read. The intensity
of the signal, corresponding with incorporation of the base, diminishes towards the end of
the reads.
1.3 Variant calling
The genetic make up of the DNA fragments at nucleotide level is determined so
far together with the location of the fragments in the genome. Hence, the consti-
tution of the viral population for each location in the genome can be investigated.
However, the errors introduced during the sequencing process both for RocheTM
as IlluminaTM may impede a powerful assessment of the low-frequency variants
within the viral population as they occur at equal or even higher frequencies than
the truly present mutations. Since there are no obvious solutions to reduce the
technical noise by further improvements of the technologies, the development of
statistical algorithms that can correct the technical noise can be pivotal. Especially,
since low-frequency variants are of interest to guide antiretroviral therapies.
Many statistical algorithms have been described in literature to call variants
at single-nucleotide level from massively parallel sequencing data. However, most
approaches are tailored to call variants in human resequencing projects where vari-
ants can be either heterologous (50%) or homologous (100%) [40] since humans
are diploid organisms having two copies of the same gene. In viral populations, the
variant frequencies cover the full range from 0 to 100% making the error correction
more challenging. Some approaches have been made to address this challenge by
employing either cut-off based filtering or statistical testing to distinguish true vari-
ants from errors. Automated filtering of potential variants based on quality scores
are popular, e.g. the VarScan algorithm [41]. Cut-off methods are, however, very
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sensitive to parameter choice [42]. Hence, the more promising methods are based
on statistical tests where variants are compared to a distribution of errors. Many al-
gorithms are primarily focused on the Roche technology [43–45] as it was the first
sequencing technology to become commercially available. These algorithms can
not always be transferred to the Illumina technology since this technology reaches
higher coverage depth and its quality scores have another interpretation. For Illu-
mina they reflect the probability of a substitution error, while for Roche they reflect
the probability of an overcall [46]. The most important methods, applicable for the
Illumina technology are the following ones. LoFreq [47] models the error proba-
bilities by using a Poisson-binomial distribution, a generalization of the binomial
distribution, where each Bernoulli trial can have a distinct success probability de-
rived from the quality scores. The program V-Phaser 2 [48] recalibrates the quality
scores prior to incorporation in the probability model together with co-occurrence
of variants within reads. ShORAH [45] is a quality score independent approach
where the errors are corrected by applying a model-based probabilistic clustering.
The number of clusters is defined using Fisher’s exact test to find patterns that
occur more frequently than expected by chance.
Most algorithms are focusing on the discovery of single-nucleotide variants.
Others, like ShORAH, can be extended to haplotype reconstruction where the co-
occurence of variants within the same gene or the same viral genome is investi-
gated. Here, the challenge is to correctly assemble the different variants as they
might occur at different DNA fragments. The linkage is done by using overlapping
reads. Hence, the assembly of the low-frequency variants [49] is challenging as
there might be little overlap. Since low-frequency variants are our main interest,
haplotype assembly should be avoided. It is better to restrict to variant calling
algorithms within the actual read length. On the other hand, linkage between the
nucleotides is lost when calling variants at the single-nucleotide level. However, to
have an immediate biological interpretation it is very important to keep the linkage
information. Anti(retro)viral drugs target certain proteins which were translated
from the viral genome by nucleotide triplets, called codons (Figure 1.3b). Sixty
four codons (43) translate to twenty different amino acids. Often mutations in
the last nucleotide do not result in a change to the amino acid sequence, which is
called silent mutation (Figure 1.3c). On the other hand, missense mutations do re-
sult in different amino acids. These latter mutations are particularly of interest and
can give insight in how the virus builds resistance against anti(retro)viral drugs.
Hence, calling variants at the codon level will allow for this immediate biological
interpretation at amino acid level. However, none of the existing tools calls vari-
ants at the codon level and retrieving linkage between single-nucleotide variants
is not straightforward. The research in this dissertation is directed to developing
variant callers that act immediately at the codon level and improve biological in-
terpretation considerably.
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Figure 1.9: a) Clusters of DNA fragments in one lane of the flowcell are plotted based on
the x,y-coordinates and divided over 120 tiles. The color indicates the number of errors
present in the sequences: black = no error, red = 1 error, blue = 2 errors, . . .. b) Boxplots
of average quality scores of the cluster sequences per tile. Tiles where more errors occur
during the sequencing process have on average lower quality scores.
1.4 Challenges
A major challenge within virology applications remain the detection of low fre-
quency variants as the errors introduced in the different steps of the sequencing
process may occur at equal or even higher frequency. The sequencing quality
scores of Illumina can help here, because they reflect the probability of a sub-
stitution error. In Figure 1.9a an image is provided of the different clusters of
DNA fragments in one lane of the flow cell distributed over 120 tiles (based on the
x,y-coordinates of the clusters). In Figure 1.9b the distribution of average quality
scores of these sequences per tile are plotted. Comparison of these two figures
reveals that tiles with more errors in the sequences, have on average lower qual-
ity scores. Hence, these quality scores will be used in a filtering approach where
the number of false-positive findings are reduced by filtering out the low quality
variants. The cut-offs are defined based on the data to account for differences in
quality between the sequencing runs. The algorithm is described in chapter 3.
The quality scores, however, do not always reflect the true error probabilities.
In Figure 1.10 the quality scores are plotted against the theoretical error probabili-
ties (green) and the observed error probabilities (orange). The Phred quality scores
(Q) are logarithmically related to the error probability (E)
Q = −10logE (1.1)
The observed error probabilities are calculated using a dataset with known vari-
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Figure 1.10: Error probability as a function of the quality scores. The observed error
probabilities are plotted together with the theoretical error probabilities in red.
ation. For each quality scores, the number of false positives are compared with the
total number of nucleotides that have the same quality score. It is clear that the
quality scores underestimate the true error probabilities. Hence, additional met-
rics might be preferred to distinguish technical noise from low-frequency variants.
The Illumina technology calls the base that corresponds with the highest intensity
among four fluorescence channels and the quality scores are derived from these in-
tensities. Extra information which can be exploited are the second best base calls,
the bases corresponding with the second highest intensity. Substitution errors can
often be corrected by these second best base calls [50]. This is investigated in
chapter 4.
1.5 Outline and contributions
The research project presented in this dissertation was granted by IWT, Baeke-
land 100679, at the end of 2010 and started officially in January 2011. Baekeland
mandates are projects assigned to consortia involving a Flemish company and uni-
versity, which is Janssen Pharmaceuticals and Ghent University respectively. The
purpose of such mandates is to support basic research that has clear economic ob-
jectives and offers added value to the company involved in the project. The first
challenge in such projects is to get the university and the company aligned. Hence,
most part of the first year was spend to understand the need of the company and
to learn the languages of the other people in these multidisciplinary teams. To
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facilitate this, I was mostly located at Janssen Pharmaceuticals in Beerse where I
could interact with the non-clinical statistics group, as well as with their clients in
discovery sciences.
1.5.1 Outline
The outcome of the project is displayed in the following chapters using the three
papers which are published or under revision.
1. Thys K., Verhasselt P., Reumers J., Verbist B.M.P, Maes B., Aerssens J.
Performance assessment of the Illumina massively parallel sequencing plat-
form for deep sequencing analysis of viral minority variants. under revision
at Journal of Virological Methods.
2. Verbist B.M.P., Thys K., Reumers J., Talloen W., Aerssens J., Clement L.,
Thas O. VirVarSeq: a low frequency Virus Variant detection pipeline for
Illumina Sequencing using adaptive base-calling accuracy filtering. 2014
Bioinformatics doi: 10.1093/bioinformatics/btu587.
3. Verbist B.M.P., Clement L., Reumers J., Thys K., Vapirev A., Talloen W.,
Wetzels Y., Meys J., Aerssens J., Bijnens L., Thas O. ViVaMBC: estimat-
ing Viral sequence Variation in complex populations from Illumina deep-
sequencing data using Model-Based Clustering. under revision at BMC
Bioinformatics.
The two developed variant callers VirVarSeq and ViVaMBC, described in chap-
ter 3 and 4, are compared in the last chapter followed by a discussion and the
valorization of the project. The papers itself resulted from the work performed
in multi-disciplinary teams which is typical in these Baekeland mandates. In the
following I will briefly specify my contributions in each of these papers.
1.5.2 Contributions
For the first paper (Chapter 2), support was given to the first author, Thys K., for
the assessment of the reporting limit which could be reached by Illumina since
the technology was not yet widely applied in the field of viral quasispecies detec-
tion. Further some support was given in writing the discussion of the final paper.
Involvement in this project was necessary for understanding the current practice
in reporting variants within Janssen Pharmaceuticals and to learn the challenges
involved.
Building further on the way of reporting I developed Q-cpileup which is de-
scribed in the second paper (Chapter 3). Q-cpileup builds further on existing code
of McLachlan and was made available from R by Joris Meys. Q-cpileup eventually
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ended up as a component of the automated pipeline VirVarSeq. Of course a thor-
ough testing on multiple samples was needed and was performed by myself. The
pipeline itself was made operational in collaboration with Reumers J. and Wetzels
Y. A users guide was written together with Wetzels Y. At the time of writing this
thesis, VirVarSeq is used within Janssen Pharmaceuticals to support some of their
clinical studies.
In the third paper (chapter 4), we went one step further and developed a model
based clustering approach. The method was developed in collaboration with my
academic promoters of Ghent University. It was implemented by myself with some
R help from Joris Meys. Again some thorough testing was needed. Help was pro-
vided here by Yves Wetzels to run the code in the amazon elastic compute cloud.
Intermediate reporting to check with reality was driven by myself. The paper and
code were written by me and code was parallelized by Alexander Vapirev to im-
prove performance.

2
Performance Assessment of Illumina
K. Thys, P. Verhasselt, J. Reumers, B.MP Verbist, B. Maes, J.
Aerssens
Performance assessment of the Illumina massively parallel sequencing plat-
form for deep sequencing analysis of viral minority variants. (2014), under
revision at Journal of Virological Methods .
Abstract Massively parallel sequencing (MPS) technology has opened new
avenues to study viral dynamics and treatment-induced resistance mechanisms
of infections such as human immunodeficiency virus (HIV) and hepatitis C virus
(HCV). Whereas the Roche/454 platform has been widely used for the detection
of low-frequent drug resistant variants, more recently developed short-read MPS
technologies have the advantage of delivering a higher sequencing depth at a
lower cost per sequenced base. This study assesses the performance character-
istics of Illumina MPS technology for the characterization of genetic variability in
viral populations by deep sequencing. The reported results from MPS experiments
comprising HIV and HCV plasmids demonstrate that a 0.5-1% lower limit of de-
tection can be readily achieved with Illumina MPS while retaining good accuracy
also at low frequencies. Deep sequencing of a set of clinical samples (12 HIV and
9 HCV patients), designed at a similar budget for both MPS platforms, revealed
a comparable sensitivity/lower limit of detection for Illumina and Roche/454. Fi-
nally, this study shows the possibility to apply Illumina’s paired-end sequencing as
a strategy to assess linkage between different mutations identified in individual vi-
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ral subspecies. These results support the use of Illumina as another MPS platform
of choice for deep sequencing of viral minority species.
2.1 Introduction
RNA viruses such as human immunodeficiency virus (HIV1) and hepatitis C (HCV)
are genetically diverse due to high replication rates, relatively small genomes and
error prone polymerases [8, 69–71]. Even within the host, RNA viruses exist
as complex populations composed of several closely related subgroups, so-called
quasi-species [10, 11]. Furthermore, host factors and immune responses apply a
selection pressure that adds to diversification of the quasi-species. A highly het-
erogeneous mixture of viral genomes enables the virus to adapt rapidly to chang-
ing environments and develop resistance to antiviral therapy. For example, HIV
reverse transcriptase is an important target for antiviral therapy but can harbor sev-
eral drug-resistant mutations, predominantly occurring within the first 350 amino
acids [72]. Similarly, the NS3 genomic region in HCV is encoding for its pro-
tease and is the molecular target for the recently approved direct antiviral drugs
Telaprevir and Boceprevir [73]. Several mutations, predominantly found in the
first 181 amino acids of NS3, have already been associated with resistance to these
drugs [74]. Sanger sequencing of PCR-generated amplicons of these target re-
gions of interest has been applied for many years as the “gold standard” to detect
drug-resistant variants in clinical samples. Although this “population sequencing”
method reliably identifies the major mutations, it fails to detect viral subspecies
present at frequencies below 20-30% in a viral population [75]. Several studies
however emphasize the clinical relevance of low frequency drug resistant vari-
ants [16,76,77] entailing the need of a more in depth characterization of sequence
variation. Massively parallel sequencing (MPS) technologies enable the deep se-
quencing of viral populations with much greater sensitivity. Roche’s 454 tech-
nology was the first available deep sequencing platform in the field and has been
used widely to detect low abundant drug-resistant variants in viral applications,
especially also because the relatively long read lengths allow to identify linked
mutations present on the same viral genome [78–80]. Today, however, alternative
massively parallel short-read sequencing technologies such as the Illumina plat-
form have become available that can provide higher sequencing depth at a lower
cost per base. The recent announcement by Roche to retract the 454 sequencing
technology from the market soon, illustrates the pressing need to evaluate alter-
native technologies. The main objective of this study was to challenge Illumina’s
GAIIx sequencing technology to at least the same sensitivity as generally accepted
for 454, where variants down to 1% can be detected [29, 49, 81]. Interestingly,
whereas novel technology developments are continuously further improving the
technical sensitivity to detect low frequency viral variants, recent reports suggests
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that the clinical impact of HIV minority species becomes potentially manifest only
for variants present above 1% [20]. Hence, especially the window between 1% and
20% might be of particular clinical interest to determine minor viral variants with
high accuracy. Whereas the higher sequencing coverage generated by the Illumina
platform would theoretically also result in a higher sensitivity as compared to the
Roche/454 technology, it is obvious that the lower limit of detection for minor-
ity variants is bound by error rates that may originate from diverse steps during
both the library preparation (typically including PCR amplification) [83] and the
sequencing process itself [84, 85]. Despite reduced error rates as a result of opti-
mized wet lab protocols [86–88], the differentiation of technical errors from true
low frequency variants remains one of the major challenges in deep sequencing.
Therefore different aspects were assessed that might contribute to the accuracy per-
formance of the Illumina technology in comparison to the established Roche/454
technology for deep sequencing applications in virology. In addition, this study
demonstrates the possibility to derive viral mutation linkage information from the
short read sequences generated by Illumina technology. When multiple clinically
relevant mutations are identified in a viral sample, it can be important to know
whether these mutations are present on the same or different viral genomes. Until
recently, this information could only be gathered through labor-intensive cloning
by limited dilution and subsequent Sanger sequencing of many individual viruses
from a clinical viral population. Today, MPS platforms can produce thousands of
clonal sequences in a rapid and cost effective way. Linkage of mutations and hap-
lotype reconstruction can be accomplished using long read MPS technologies such
as Roche/454, albeit constrained by the physical read length (approximately 400
base pairs) [89]. Haplotype reconstruction is particularly challenging for short-
read technologies [90], but Illumina’s paired-end sequencing approach enables
linkage analysis beyond the limit of the read length itself. Whereas this approach
was originally developed to improve read alignment, this study demonstrates its
concomitant value for linkage analysis.
2.2 Materials and methods
2.2.1 Plasmid samples
Two different HCV plasmids were used, each comprising the viral NS3-4A frag-
ment. Site-directed mutations have been introduced into the con1b replicon plas-
mid pFK_i341_PI Luc_NS3-3’_ET (wild type) as described earlier [91,92]. These
plasmids (wild type and mutant) differ only in two single nucleotides from each
other, as confirmed by Sanger sequencing. For MPS experiments, the fragment en-
compassing the NS3-4A region (2.4 kb) was PCR-amplified using region-specific
primers [80] and Phusion hot start high-fidelity DNA polymerase, Finnzymes Oy,
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Espoo, Finland) according to manufacturer’s instructions. PCR reactions were
done in triplicate and subsequently pooled to reduce possible PCR bias. Similarly,
four HIV plasmids comprising the reverse transcriptase (RT) gene in a pGEM-3zf
background were used in the study. In an experiment that focused on the evaluation
of errors introduced during the MPS sequencing process, the whole plasmid was
sequenced thereby avoiding potential errors that might otherwise be introduced
during target amplification.
2.2.2 Clinical samples
Viral RNA was extracted from plasma samples collected from HCV and HIV pa-
tients using the automated NucliSENS R© easyMAG R© system (bioMérieux). The
viral RNA (16 µl) from HCV patients was reverse transcribed using random hex-
amers (Invitrogen, Carlsbad, CA) and AccuscriptTM high fidelity reverse transcrip-
tase (Agilent Technologies, Santa Clara, CA). The resulting cDNA (2 µl) was used
as starting material for amplification of a fragment encompassing the HCV NS3-
4A region (2.4 kb) by two-round nested PCR using gene-specific primers [93] and
KOD DNA polymerase (Novagen, Madison, WI). For HIV samples, viral RNA
(10 µl) was reverse transcribed and cDNA was amplified in a one-step PCR us-
ing gene-specific primers [94] (Super-ScriptTM III One-Step RT-PCR System with
Platinum R© Taq DNA Polymerase (Life Technologies, Carlsbad, CA). A 1.9 kb
amplicon encompassing the HIV protease (PR) - RT region was subsequently am-
plified in a nested PCR using the Expand high fidelity PCR system (Roche Applied
Science, Pesberg, Germany) or Phusion hot start high-fidelity DNA polymerase
(Finnzymes Oy). For both HIV and HCV, PCR reactions were done in sevenfold
and subsequently pooled to reduce possible PCR bias.
2.2.3 Amplicon purification and quantification
Prior to fragmentation and deep sequencing, all amplicons, derived from either
plasmids or clinical samples, were purified using the QIAquick PCR purifica-
tion kit (Qiagen, Venlo, Netherlands) and QIAquick gel extraction kit (Qiagen)
or Agencourt Ampure XP (Beckman Coulter Genomics, Danvers, MA). Samples
were quantified using the Quant-iTTM PicoGreen R© dsDNA kit (Life Technolo-
gies).
2.2.4 Illumina deep sequencing
Following Illumina’s standard protocols, the DNA (0.1-0.5 µg) was fragmented to
an average length of 200 bp using the Covaris R© E210 system (Covaris, Woburn,
MA). The ends of the fragmented DNA were repaired, adenylated and Illumina
compatible adaptors (Index PE Adaptor Oligo Mix (Illumina, San Diego, CA)
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or barcode-included adaptors from NEXTflexTM DNA Barcodes (Bioo Scientific,
Austin, TX)) were ligated using the SPRIworks Fragment Library System I (Beck-
man Coulter Genomics). In case when Index PE Adaptor Oligo Mix adaptors were
used, fragments were indexed using Illumina compatible barcodes by the Multi-
plexing Sample preparation Oligonucleotide Kit (Illumina). Next, the library was
enriched during 12 cycles of PCR. Enriched fragments were visualized on a Bioan-
alyzer (Agilent Technologies) for quality control and quantification. Next, samples
were pooled according to the specific experimental setup, prior to applying on the
Illumina cluster station for cluster generation using the TruSeq PE Cluster Kit v2
(Illumina). A multiplexed paired-end sequencing run of 147 cycles was executed
using the TruSeq SBS Kit v5 (Illumina) on the Genome Analyzer IIx (GAIIx)
(Illumina).
2.2.5 454 deep sequencing
Deep sequencing by 454 was performed as described earlier [94]. In short, DNA
was fragmented to an average length of 500 bp using the Covaris R© E210 system
(Covaris). Using the SPRIworks Fragment Library System II (Beckman Coulter
Genomics), the ends of the fragmented DNA were repaired and adenylated and 454
sequencing adaptors were ligated to allow for sample multiplexing in sequencing
lanes on the Roche GS FLX instrument. Fragments were indexed using the GS
FLX Titanium Rapid Library MID Adaptors kit (Roche). Next, samples were
pooled according to the experimental setup. Clonal amplification was performed
by emulsion PCR (GS FLX Titanium emPCR Kit, Roche). Finally, samples were
sequenced using the GS FLX Titanium Sequencing Kit (Roche) on a GS FLX
instrument (Roche).
2.2.6 Initial MPS data processing
First, a consensus sequence representing the majority of the underlying viral pop-
ulation was derived for each of the samples. This consensus sequence was either
obtained through independent Sanger population sequencing, or derived from the
available MPS reads after mapping against a universal reference sequence (HIV
or HCV). Next, all individual MPS sequence reads were mapped for each sam-
ple against their own consensus sequence, using CLCBio Workbench (CLCBio,
Aarhus, Denmark). Mapping parameters were set to favor single nucleotide mis-
matches over single nucleotide insertions or deletions considering the viral coding
background. A similarity of 80% with the reference was decisive for mapping 50%
of the read length allowing low quality ends of the read to be trimmed for further
analysis. Minority variant analysis focused on a subset of the alignment, namely
the 1050 bp region corresponding to HIV reverse transcriptase amino acids 1-350
and the 543 bp region encoding the HCV protease amino acids 1 to 181. Codon
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variants were determined per amino acid position of the region of interest (HIV:
amino acids 1-350 of RT gene; HCV: amino acids 1-181 of NS3 gene) and their
relative frequencies were calculated as the proportion of reads containing a spe-
cific codon divided by the coverage at that position. Relative frequencies of codon
variants were calculated separately for each sequencing direction (forward and re-
verse); the lowest observed frequency (either forward or reverse) per codon variant
was reported. As demonstrated earlier, the insertion of errors during high through-
put sequencing is highly dependent on the direction of the sequence read hence,
bi-directionality is often used as a factor for error correction/filtering [84, 95, 96].
By means of additional error filtering for Illumina sequencing, codons with at least
one nucleotide with a quality value lower than 30 (representing an error rate of 1
in 1000 [56] were not taken into account.
2.2.7 Coverage depth analysis
In order to determine the sequencing depth needed to maintain accurate quantita-
tive assessment of minor variant frequencies, 4 mixtures containing different ratios
(1:200, 1:100, 1:50, and 1:10) of wild type and mutant HCV plasmids harboring
two codon variant at NS3 position 36 and 155 were deep sequenced using the Il-
lumina platform. Random subsets of sequence reads (0.1, 0.2, 0.5, 1 and 2 million
reads) were generated from the total dataset (average 7.4 million reads per sam-
ple) to simulate different levels of coverage (± 1,000x, 2,000x, 5,000x, 10,000x,
and 20,000x, respectively; performed in triplicate). For each coverage depth, fre-
quencies of all codon variants (errors included) at NS3 positions 36 and 155 were
calculated.
2.2.8 Linkage analysis
The degree of linkage between observed mutations at amino acid positions 101
and 138 in the HIV-RT gene, located 114 bp apart - and thus only identifiable on
different individual reads (only 70 bp read length in the Illumina run) – was cal-
culated. DNA was fragmented in approximately 200 bp fragments during sample
preparation and subsequently paired-end sequenced. The sequence information
of both ends of the same DNA fragment is available and can be coupled through
positional information (XY coordinates of the Illumina flow cell) hence linked
mutations can be derived for individual viral subspecies. From this information,
percentages of linked mutations in fragments containing all possible combinations
of codon variants were derived.
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NS3_36 NS3_155
Expected freq (%) Observed freq (%) Observed freq (%)
10 11.28 10.35
2 2.37 2.14
1 0.91 0.83
0.5 0.44 0.32
0 0 0
Table 2.1: Expected and observed frequencies of a spiked-in HCV-NS3/4A plasmid
harboring two codon variants? as revealed by Illumina deep sequencing. ?Mutant HCV
NS3/4A plasmid, carrying two single codon variants (codons 36 and 155) was spiked-in at
different ratios (1:10, 1:50, 1:100, 1:200 and 0:1) versus the wild-type plasmid.
2.3 Results
2.3.1 Accuracy of Illumina deep sequencing
Deep sequencing holds the promise to quantitatively assess the presence of minor-
ity variants in viral populations, which cannot be reliably determined by Sanger
sequencing. The accuracy of deep sequencing on the Illumina GAIIx platform
was evaluated by spiking a HCV plasmid carrying two codon variants in the NS3
region at different ratio’s (1:10, 1:50, 1:100, 1:200, and 0:1) into wild type HCV
plasmid, corresponding to variant frequencies between 10% and 0%. Targeted
deep sequencing of the fragment encoding amino acids 1-181 of HCV NS3 re-
vealed an average coverage depth of 64,877x, ranging from 32,574x to 114,925x,
for the 5 plasmid mixtures. Comparison of the expected and observed frequencies
for all spiked-in variants demonstrates the highly accurate quantification that can
be achieved with ultra-deep sequencing (Table 2.1). Although theoretically such
high coverage would allow the detection of variants far below 0.5%, the presence
of errors introduced by wet lab preparation methods and sequencing complicates
the reliable detection of low frequency variants. For the plasmid mixtures, each
codon differing from the consensus sequence other than the spiked-in variant is
considered to be an error, although one cannot exclude that some of the observed
sequence differences are real and could be attributed to errors introduced during
plasmid preparation. Figure 1 shows the observed frequency of the spiked-in muta-
tions in the background of all other variants observed in the HCV NS3 region. This
analysis confirms the reliable detection of variants spiked-in at frequencies above
0.5% (Figure 2.1A), but also demonstrates a high abundance of low-frequency er-
rors that may obscure the identification of true variants present at low frequency
(Figure 2.1B).
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Figure 2.1: Frequencies of codon variants (in percentage) per position in HCV-NS3
represented in (A) absolute and (B) logarithmic scales. HCV plasmid carrying two codon
variants was spiked at different ratios (1:10, 1:50, 1:100, 1:200, 0:1) in wild-type plasmid.
Each dot represents a single codon variant, with the spiked-in variants depicted in black
color and all other detected codon variants, considered to be errors, in gray. A codon
variant was defined as any codon sequence that is different from the consensus codon
sequence.
2.3.2 False discovery rate of Illumina deep sequencing
Next, the false discovery rate (FDR) of viral minor variants was assessed through
deep sequencing of wild type plasmids. Four plasmids carrying HIV-RT amino
acids 1-350 and 2 plasmids carrying HCV NS3 amino acids 1-181 were analyzed
using the Illumina GAIIx sequencing platform. Average read numbers of approxi-
mately 2.6 and 6.9 million yielded an average coverage of 13,739 and 60,137 reads
per position for the HIV and HCV plasmids, respectively. Errors from the refer-
ence plasmid sequence were observed in 269,193 out of 57,631,296 sequenced nu-
cleotides (0.47%) for the 4 HIV plasmids, and in 172,295 / 65,262,693 sequenced
nucleotides (0.26%) for the 2 HCV plasmids. At codon level, this implied 144,610
/ 19,210,432 (0.75%) incorrect codons for the 4 HIV plasmids, and 171,726 /
21,754,231 (0.79%) incorrect codons for the 2 HCV plasmids. The observed error
rate at codon level is higher as one nucleotide change in the triplet is enough to
change the codon. Because sequencing errors are not randomly distributed and
can vary considerably per position [84], the application of the average error level
as a fixed cut-off appears not sufficiently stringent to accurately discriminate true
variants from the false positive background noise. Whereas in all examined plas-
mids, the vast majority of observed variants were found at low frequencies (P90
at 0.2%-0.3%), few of them reached frequencies up to 1% (Figure 2.2). The false
discovery rate for the HIV and HCV plasmids was calculated at increasing cut-off
values (Figure 2.3), demonstrating that the FDR for the detection of minor vari-
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Figure 2.2: Box plots representing relative frequencies of variants in 6 clonal samples,
comprising (A) HIV-RT plasmids (n=4) or (B) HCV-NS3 plasmids (n=2), observed by
Illumina sequencing. Each dot represents a single variant (codon sequence different from
the consensus codon sequence). N indicates the total amount of false positive variants.
The black line represents the 90th percentile range (P90); the white line depicts the
median frequency of minority codon variants.
ants converges to zero for all plasmids well below a cut-off value of 1%. It should
be noted that the above analysis based on plasmid sequences might underestimate
the FDR in clinical viral RNA samples, because plasmid DNA samples do not un-
dergo a reverse-transcription PCR step during library preparation. Since this latter
step could be an important source of sequencing errors, AccuScript high-fidelity
reverse transcriptase (Stratagene) which displays a threefold higher fidelity (error
rate 2x 10-5) than commonly used MMLV reverse transcriptase [136] was utilized
for the processing of clinical viral RNA samples.
2.3.3 Coverage depth analysis
Given the large discrepancy between coverage depths used in typical deep se-
quencing experiments using Illumina and Roche/454 technologies, an experiment
was designed aiming to determine the sequencing depth needed to maintain accu-
rate quantitative assessment of minor variant frequencies. Sample mixtures con-
taining different ratios (1:10 up to 1:200) of HCV plasmids harboring two codon
variants (at NS3 position 36 (GTC→ATG) and 155 (CGG→AAA) versus wild
type) were sequenced using the Illumina GAIIx sequencing platform. On aver-
age, sequencing yielded 7.4 million reads per sample mixture. Random subsets
of sequence reads (0.1, 0.2, 0.5, 1 and 2 million reads) were generated in tripli-
cate from the total dataset in order to mimic different levels of coverage (1,000x,
2,000x, 5,000x, 10,000x, and 20,000x, respectively). For each sequencing depth,
all codon variants identified at NS3 position 36 were reported, errors included
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Figure 2.3: False discovery rate (FDR) in function of cut-off value for HIV-RT (n=4) and
HCV-NS3 (n=2) plasmids. FDR was calculated as the amount of false positives (FP)
divided by the total amount of positives (true and false). True positives (TP) were defined
as consensus codons covering the region of interest (350 codons per HIV plasmid and 181
codons per HCV plasmid).
(Figure 2.4). This visualization enables to evaluate both the accurate detection
of the NS3 variant as well as the quantitative assessment of codon frequencies.
For samples comprising the NS3 variant spiked-in at 10% or 2%, the correct vari-
ant could be reliably detected above the error frequencies for all coverage depths
(Figure 2.4A and B). Observed variant frequencies ranged from 9.01% to 11.01%
and from 1.85% to 2.65%, respectively, well above the maximum error frequen-
cies (0.13% to 0.55%) observed at this position. The standard deviation of the
observed frequencies decreased at higher coverage, indicating more precise vari-
ant frequency estimations at higher sequencing depth. Although variant frequency
was generally underestimated for plasmid mixtures with 1% spiked-in variants
(frequency ranging from 0.24% to 1.07%), the estimated frequency improved with
increasing coverage (Figure 2.4C). At the lowest coverage depth tested (±1,000
reads), it was impossible to distinguish the spiked-in variant from the errors in
two out of three replicates. Finally, NS3 variants spiked-in at 0.5% could only be
distinguished from errors at the highest tested coverage’s (Figure 2.4D).
2.3.4 Illumina versus 454 deep sequencing
In order to assess the lower limit of detection in clinical samples, 12 isolates of
HIV patients and 9 isolates of HCV patients were analyzed in parallel with both
Illumina and Roche/454 sequencing platforms. For HIV isolates, the HIV PR-
RT (1.9 kb) region harboring the first 350 amino acids of HIV-RT were amplified
and sequenced, while a 2.4 kb amplicon (encoding HCV NS3-4A) was designed
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Figure 2.4: Accuracy of codon variant frequency estimation in function of sequencing
depth. An HCV plasmid carrying two codon variants (at position 36 and 155 of NS3) was
spiked at different ratios (1:10, 1:50, 1:100, 1:200) in wild-type plasmid. The individual
graphs show the frequency of all observed codon variants at amino acid position 36 of
NS3 for different levels of sequencing coverage. The coverage (N) is the result of random
sampling (S) of sequence reads from the original dataset (1, 2, 5, 10 or 20 x105 reads).
Samplings were performed in three-fold. Each circle represents one observed codon
variant. The filled circle represents the spiked codon variant (ATG) whereas open circles
represent all other codon variants which are considered to be errors. The dotted line
represents the expected frequency of the spiked variant.
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to inspect the first 181 amino acids of the HCV NS3 protein. Illumina sequenc-
ing yielded on average 3.8 million reads for the HIV-RT amplicon and 1.4 mil-
lion reads for the HCV-NS3 amplicon, resulting in an average coverage of 99,660
and 19,718, respectively. At a comparable cost, 454 sequencing resulted in av-
erage read numbers of 53,899 and 15,497 and an average coverage of 8,613 and
1,347 reads per position for HIV and HCV, respectively. Minor variant frequen-
cies observed by both technologies were compared for all clinical isolates. Above
the conservative 1% cut-off, variant frequencies observed in the two technologies
were highly correlated (r2 = 0.97, n = 835, p < 0.0001 for the HIV isolates;
r2 = 0.96, n = 266, p < 0.0001 for the HCV isolates) (Figure 2.5A and B). Be-
low this 1% frequency threshold, bigger discrepancies between the frequencies are
observed. Variants detected by either of both platforms -above the pre-defined 1%
cut-off- were considered as possible false positives/negatives. To account for small
bias in frequency estimation, all variants that were detected at frequencies less than
0.5% in one platform and above 1% in the other were investigated further. For
HIV samples, 1 variant was identified with Illumina that was present below 0.5%
on Roche/454 whereas 38 variants detected with Roche/454 were not observed at
frequencies above 0.5% with Illumina. All the latter variants were located in ho-
mopolymeric stretches of nucleotides and were therefore considered Roche/454
false positives. For the HCV samples, an equal amount of variants were seen with
Illumina (32) that were present below 0.5% with Roche/454 and vice versa (29).
These errors occurred at maximum frequencies of 3.3% and 2.0% respectively.
No trend in the nature of mutations could be appointed for HCV. However, due to
the low coverage of the 454 experiment a bias in accurate estimation of frequen-
cies cannot be excluded which can lead to both over- and under-estimation of 454
variants compared to Illumina.
2.3.5 Linkage analysis
In addition and complementary to a reliable detection and quantitative assessment
of variant frequencies, the study of viral populations in clinical isolates often in-
volves the study of linkage between resistance-associated mutations. Given the
relatively short read length of Illumina sequencing technology, it is often not
considered as an appropriate technology to perform such analysis. This study
demonstrates that it is feasible to investigate linkage using the Illumina sequenc-
ing platform, given the appropriate experimental conditions are used. The com-
plete HIV-RT region (1.9 kb) was amplified from 9 clinical isolates harboring
IAS-USA resistance-associated mutations (RAM) K101E and/or E138K (accord-
ing to Sanger population sequencing). Subsequent library preparation for the Illu-
mina GAIIx involved a fragmentation step revealing average fragment sizes of
200 bp, which should be large enough to contain both RAM positions in sin-
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Figure 2.5: Scatterplot representing relative frequencies of codon variants detected by
Illumina versus Rochde/454 sequencing of the HIV-RT region of 12 clinical samples (A)
and HCV-NS3 region of 9 clinical samples (B). Codon variants are defined as codons
different from the consensus codon of the sample. Each dot represents one codon variant of
one sample. Frequencies are plotted in log-transformed scale. The dotted lines indicate the
1% cut-off level (both for Illumina and Roche/454), representing the analytical sensitivity
typically applied for Roche/454 sequencing.
gle DNA fragments. All isolates were sequenced with 70 bp paired-end reads
at the Illumina GAIIx sequencing, resulting in 7.5 million reads (on average)
per sample. Following the mapping of the reads (yielding an average coverage
of 213,355x and 251,117x at positions 101 and 138, respectively), variant fre-
quencies of K101E and E138K were calculated. A strong inverse correlation
(r2 = 0.989, p < 0.0001) was observed between the frequencies of both muta-
tions (Figure 2.6), suggesting mutual exclusivity of both mutations. Next, linkage
analysis was performed to assess whether both mutations could co-exist in one vi-
ral genome. The dataset of sequencing reads was filtered to contain only paired
reads (sequences from both ends of the same fragment) spanning both positions
101 and 138, revealing on average (for the 9 isolates) 45,040 paired reads cov-
ering both positions of interest. The majority of paired reads from all 9 isolates
harbored only one of the 2 mutations (E138K and K101E) in combination with
wild-type (49% and 40%, respectively). Five percent of all paired reads were wild
type at both positions and 2% carried other variants, leaving only 4% of all the
reads (from all isolates) harboring both mutations (Table 2.2). The probability of
observing mutant E138K independent of the other mutation is 53%, while it is
44% for mutant K101E. This implies that the probability of observing both ob-
servations together, if they are independent from each other, is 23%. Hence, the
observed 4% is far below and hence the mutations E138K and K101E are mutually
exclusive and appear rarely on the same viral genome.
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Sample K101K/ K101K/ K101K/ K101E/ K101E/ K101E/ K101? / K101? / K101? / Total
E138E E138K E138? E138E E138K E138? E138E E138K E138?
1 172 215 4 41,609 508 303 357 6 2 43,176
(<1%) (<1%) (<1%) (96%) (1%) (1%) (1%) (<1%) (<1%)
2 5,021 6,626 80 30,168 1,632 126 1,112 103 6 44,874
(11%) (15%) (<1%) (67%) (4%) (<1%) (2%) (<1%) (<1%)
3 2,947 9,042 6 31,819 2,656 26 91 34 0 46,621
(6%) (19%) (<1%) (68%) (6%) (<1%) (<1%) (<1%) (0%)
4 2,300 7,122 131 17,628 2,516 77 54 30 0 29,858
(8%) (24%) (<1%) (59%) (8%) (<1%) (<1%) (<1%) (0%)
5 2,880 8,311 41 19,033 3,663 114 80 40 0 34,162
(8) (24%) (<1%) (56%) (11%) (<1%) (<1%) (<1%) (0%)
6 2,829 19,537 80 12,657 2,593 65 48 82 0 37,891
(7%) (52%) (<1%) (33%) (7%) (<1%) (<1%) (<1%) (0%)
7 1,315 37,016 54 4,651 1,201 5 16 77 0 44,335
(3%) (83%) (<1%) (10) (3%) (<1%) (<1%) (<1%) (0%)
8 1,571 52,116 3,736 2,587 1,947 341 15 144 8 62,465
(3%) (83%) (6%) (4%) (3%) (1%) (<1%) (<1%) (<1%)
9 1,243 58,599 460 833 633 6 7 193 1 61,975
(2%) (95%) (1%) (1%) (1%) (<1%) (<1%) (<1%) (0%)
Total 20,278 198,584 4,592 160,985 17,349 1,063 1,780 709 17 405,357
(5%) (49%) (1%) (40%) (4%) (<1%) (<1%) (<1%) (<1%) (100%)
Table 2.2: Clonal distributions of observed variants at codon positions 101 and 138 in the
HIV RT gene. The paired-end Illumina sequencing method enabled to calculate counts
(and row percentages) of paired sequence fragments for each of the different possible
combinations of codon variants at position 101 and 138 (residing on the different sequence
fragments). Observed amino acid variants are wild type (K101K and E138E),
resistance-associated mutations (K101E and/or E138K) or any other (designated as
K101? or E138 ?).
Figure 2.6: Correlation between the observed frequencies of resistance-associated
mutations K101E and E138K in HIV RT in samples from 9 HIV-infected subjects. The
presence of mutations at these two amino acid positions was derived from paired-end
Illumina sequencing.
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2.4 Discussion
Recent reviews highlight the growing importance of MPS for different applica-
tions in virology [97–99]. A major application is the so-called deep sequencing
of targeted regions in order to detect minority variants within the viral population
and their possible clinical impact on antiviral therapy [23, 76–79, 100–104]. Until
recently, Roche’s 454 has been the platform of choice to reliably detect minority
variants down to a frequency of 1% [29, 81], which was recently suggested to be
sufficient to identify minority variants with clinical impact [82]. However, alterna-
tive technologies to address the same application are needed urgently as Roche is
planning to fade out the 454 technology by mid-2016. This study evaluated the use
of the Illumina sequencing platform for the same application. Using plasmid data
it was shown that at least the same or a lower cut-off value of 1% can be applied
to Illumina’s short-read sequencing technology while maintaining a comparable
accuracy. A major difference between the two sequencing platforms is the out-
put volume of sequencing data per run (GAIIx reaches 320 million reads per run
while 454 reaches 1 million reads per run). This implies that for a comparable se-
quencing cost, more than 10-fold higher coverage can be achieved using Illumina’s
technology, hence suggesting a higher sensitivity compared to 454. Both this study
and other comparisons in literature between the two platforms indeed provide ex-
perimental support for this statement [90,105,106]. Although in theory the higher
sequencing depth would enable a lower limit of detection for minority variants
as compared to Roche/454, the present study evidences that the cut-off value is
mostly bound by error rates introduced during library preparation and sequencing.
Recent studies have reported that error correction or data filtering could help re-
ducing the error rate [44, 47, 107–110] suggesting that a lower limit of detection
might be feasible by incorporating these methods during variant calling. As ana-
lytical sensitivity cannot be infinitely improved by increasing the coverage depth,
one could benefit from the large sequencing output volume from the Illumina plat-
form by processing more samples per run at a cost comparable to Roche/454. The
experimental set up can be further tailored by running experiments on even higher
throughput (HiSeq2000 or HiSeq2500) or lower throughput (MiSeq) Illumina in-
struments. The reported analysis demonstrate clearly that lowering the coverage
depth does not necessarily affect the noise level nor alters the detection accuracy
of low frequency variants. A minimal coverage of 2,000x appears to be required,
however, in order to ensure an accurate quantitative assessment of minor variant
frequencies.
This study demonstrates that the short read technology of Illumina is equally
suitable as roche/454 for an in depth characterization of sequence variation at in-
dividual codon level. However, the short reads hamper the performance of global
haplotype reconstruction as addressed in different studies [90] and limit the direct
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detection of linkage between mutations on individual single sequencing reads. The
smart use of Illumina’s paired-end technology enables linkage analysis beyond the
limit of a single sequencing reads. Modulating and selecting the appropriate frag-
ment sizes during library preparation allows detecting linkage in larger fragments
– which is only limited by the maximal fragment size that can generate sufficient
clustering on the Illumina flow cell, hence similar to or above the sequencing read
length generated by 454. A drawback of the approach is, however, the need to de-
fine upfront the targeted fragment size, which limits the linkage detection to a pri-
ori defined codon positions. In the current study, the existence of linkage between
two important IAS-USA resistance-associated mutations (K101E and E138K) in
HIV-RT was explored. The paired-end sequencing analysis suggests mutual ex-
clusivity of both mutations, as only 4% of paired sequence reads that cover both
codon positions showed linkage between mutations K101E and E138K. Of note,
protocols for paired-end sequencing with longer read lengths have meanwhile be-
come available on various Illumina instruments (HiSeq2000: 100 bp, HiSeq2500:
150 bp, MiSeq: 300bp). This implies that contiguous sequences of 550 bp can be
achieved on MiSeq by assembling the paired 300 bp reads through a 50 bp overlap,
which is a similar size as the single read lengths generated on roche’s GS FMX and
GS Junior instruments.
2.5 Conclusion
Whereas Roche/454 MPS has for a long time been the method of choice for deep
sequencing of viral minority species, in particular because the relatively long read
lengths allow identifying linked mutations present on the same viral genome, the
Illumina technology was suggested as an interesting alternative for studying low-
frequent sequence variants because of its lower cost per sequenced base in com-
bination with the gradually increasing read lengths. The assessment of the per-
formance characteristics of Illumina technology in specific virology applications
demonstrates and supports its use as another deep sequencing platform of choice,
especially because the higher sequencing output volume from the Illumina plat-
form enables the simultaneous processing of more samples for the same cost as
compared to Roche/454 sequencing. However, whereas the high sequencing cov-
erage that can be obtained by Illumina technology results in an accurate estimation
of minor variant frequencies, the experimental data show that this does not auto-
matically imply a lower detection limit for the identification of minor variants.
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Abstract In virology, massively parallel sequencing (MPS) opens many op-
portunities for studying viral quasi-species, e.g. in HIV-1 and HCV-infected pa-
tients. This is essential for understanding pathways to resistance, which can sub-
stantially improve treatment. Although MPS platforms allow in-depth character-
ization of sequence variation, their measurements still involve substantial techni-
cal noise. For Illumina sequencing, single base substitutions are the main error
source and impede powerful assessment of low-frequency mutations. Fortunately,
base calls are complemented with quality scores that are useful for differentiating
errors from the real low-frequency mutations. A variant calling tool, Q-cpileup, is
proposed, which exploits the quality scores of nucleotides in a filtering strategy to
increase specificity. The tool is imbedded in an open-source pipeline, VirVarSeq,
which allows variant calling starting from fastq files. Using both plasmid mix-
tures and clinical samples we show that Q-cpileup is able to reduce the number of
false-positive findings. The filtering strategy is adaptive and provides an optimized
threshold for individual samples in each sequencing run. Additionally, linkage in-
formation is kept between single-nucleotide polymorphisms as variants are called
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at the codon level. This enables virologists to have an immediate biological in-
terpretation of the reported variants with respect to their antiviral drug responses.
A comparison with existing SNP callers reveals that calling variants at the codon
level with Q-cpileup results in an outstanding sensitivity while maintaining a good
specificity for variants with frequencies down to 0.5%.
3.1 Introduction
RNA viruses such as HIV-1 and HCV exist in their host as complex populations
composed of several closely related subgroups. They are referred to as quasi-
species and originate from high and error-prone replication rates [10]. This hetero-
geneous mixture of genomes allows a viral population to rapidly adapt to changing
environments. The fittest mutants outcompete the others, allowing the virus to de-
velop resistance to antiviral therapy. The characterization of sequence variation
within the viral population is key for understanding pathways to resistance, but the
identification of low-frequency variants remains challenging [54, 57].
Until recently, the genetic diversity of a virus population could be assessed
only through genotyping by Sanger sequencing, which provides information on
only the most abundant viral variants. Massively parallel sequencing technolo-
gies allow for a more in-depth characterization of sequence variation, including
low-frequency viral strains. However, their measurements still involve substantial
technical noise, complicating the analysis [37, 52]. Pyrosequencing, commercial-
ized by Roche 454, was the most common sequencing method for viral popu-
lation sequencing [53]. The recent announcement by Roche to retract the 454
technology from the market by mid-2016 illustrates the pressing need to evalu-
ate and implement alternative technologies. Recently Illumina’s sequencing tech-
nique has strengthened its position in this field [67]. Illumina also complements
the sequenced nucleotides with quality scores (Q) [56] that reflect the base-calling
substitution error probability. The 454 quality scores, however, do not have such
an intuitive interpretation [46]. Filtering based on quality scores [64] has already
proven valuable to reduce false-positive findings. It often involves the use of a
hard quality threshold. Unfortunately, this does not account for variation in qual-
ity between runs resulting in too stringent or too relaxed thresholds.
Most variant calling tools focus on the detection of single-nucleotide polymor-
phisms (SNPs) [44, 47] or perform haplotype reconstruction [45, 66]. Haplotype
assembly has its weakness in the detection of low-frequency variants [49], whereas
the latter is our main interest. Instead, we prefer to call variants within the read
length to avoid challenges encountered in the haplotype reconstruction. On the
other hand, linkage between the nucleotides is lost when calling variants at the
SNP level. In this contribution we introduce a novel strategy for calling variants
at the codon level (nucleotide triplets), which facilitates immediate biological in-
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terpretations, particularly in virology applications where drug-target regions are of
interest.
In this chapter, we present an innovative approach for variant calling at the
codon level, named Q-cpileup, that reduces the number of false-positive findings
by exploiting the quality scores of the nucleotides generated by sequencing. Our
thresholding strategy is adaptive to provide an optimized threshold for individ-
ual samples in each sequencing run. Q-cpileup is imbedded in a pipeline, called
VirVarSeq, which starts from fastq files.
3.2 Methods
Several samples were sequenced using Illumina’s genome analyzer (GA) IIx ac-
cording to manufacturing protocols (described in Chapter 2). The VirVarSeq pipeline
proceeds as follows:
1. The sequenced reads are aligned against a reference sequence using the
Burrows-Wheeler Aligner Tool (BWA) [59].
2. Based on this alignment, a consensus sequence is defined.
3. A realignment is performed against this consensus. This strategy of iterative
mapping will increase coverage especially in samples where the consensus
strongly deviates from the reference (see appendix A, Figure 1).
4. After alignment, Q-cpileup is executed, which consists of a three-step anal-
ysis:
a) In the first step, the quality scores of the codons in the reading frame of
interest are retrieved.
b) Next the threshold is determined dependent on the quality of the run.
c) Finally the filtered codon table is constructed.
The VirVarSeq pipeline, which runs from fastq to the filtered codon table,
is available at http://sourceforge.net/projects/virtools/?source=directory together
with a users guide (see appendix B). All reads containing indel errors are removed
before running Q-cpileup. It is hereby assumed that indels will result in non-viable
virus. In some rare occasions, however, there might be an insertion mutation at the
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Position Ref Codon Count Coverage Frequency Mean
Codon (%) Q
001 GGG AGG 167 18,958 0.88 35
001 GGG GTG 83 18,958 0.44 16
001 GGG TGG 15 18,958 0.08 33
001 GGG GGG 18,693 18,958 98.6 37
002 CGT CAG 461 19,217 2.4 30
002 CGT GGG 20 19,217 0.1 5
Table 3.1: Example of a frequency table at the codon level. The different codons observed
in a sample are counted at each codon position of the reference genome and their
frequencies are calculated using the coverage at that particular position. The quality
scores are summarized by averaging the minimum quality scores of the codons. Position:
amino acid position of the reference. Ref: codon of the reference genome at a particular
position. Codon: codon present in a sample at a particular position. Count: the number of
times a particular codon occurs in the cpileup at a particular position. Coverage: the
number of reads that fully cover a particular codon position. Frequency: Count/Coverage.
Mean: Average of the minimum quality scores of a particular codon at a particular
position.
codon level, which can be investigated in a separate analysis (see indel Table ap-
pendix A). Below, the different steps from Q-cpileup will be explained in more
detail.
3.2.1 Quality of codons
A pileup of read bases is generated using the alignments to a consensus sequence.
In analogy with mpileup of samtools, for which the base-pair information at each
reference position is described, cpileup describes the codon information at each
amino acid position of the reference genome. For each position in the reference
genome, the different codons are reported together with one quality score for each
codon. This requires that the quality scores of the three nucleotides within a codon
have to be summarized. A comparative analysis of different summarizations re-
vealed that the weakest link, i.e. minimum quality score of the three nucleotides
in the codon, provided the best separation between low- and high-quality codons
(see Appendix A, Figure 2). This minimum quality score represents the codon’s
nucleotide with the highest probability of being a sequencing error. A codon ta-
ble is built based on the pileup where for each codon position of the reference the
different codons within a sample are reported together with their frequency (Ta-
ble 3.1). The minimum quality scores of the codons at a particular position are
averaged to give a rough idea about the overall quality. However the individual
minimum quality scores of the codons themselves is used in subsequent analysis.
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3.2.2 Q-intersection threshold (QIT)
The distribution of the minimum quality scores was checked and compared for one
particular sample sequenced in two different runs and three different lanes reaching
an average coverage of around 30,000 (Figure 3.1). The shape of the distributions
can be approximated by a mixture distribution with three truncated normal com-
ponents (see appendix A for model selection and goodness of fit in appendix A,
figure 3). Truncation is performed at the lower and upper ends of the quality score
range. The first mode represents a point probability at quality score 2, which is
the lowest Illumina quality score. This is due to an artifact created by Illumina’s
base caller. Read ends with a segment of mostly low quality (Q15 or below) are
given a quality score of 2. The second component distribution is a distribution of
low quality scores, reflecting the sequencing error distribution. Finally, the high-
est mode, close to 40, originates from a distribution of reliable calls. Note, that
the mixture of three normal components for the errors and reliable calls should
be considered only as a working assumption and that neither trimming nor filter-
ing of the data is required before fitting the mixture models. The EM algorithm
of McLachlan [60] will be applied for fitting these normal mixture models. We
have written an R-wrapper to run the original Fortran code of McLachlan which is
embedded in the pipeline VirVarSeq. The EM algorithm was initialized by setting
the three modes at 2, 10 and 35 and the variances at 0.8 for the point probability
and 40 for the other two distributions. The marginal error probability, the sum of
mixing proportion of the distributions at 2 and 10, was set to 15%.
The bulk of quality scores was high, indicating a majority of reliable calls
in the dataset (green distribution in Figure 3.1). At the other end, a clear point
probability at the quality score of 2 was seen. The red distribution in Figure 3.1
corresponds to low- quality codons that are likely to be sequencing errors. There
are several criteria to define a threshold for filtering the low-quality codons and
for distinguishing between errors and reliable calls. An approach is chosen that is
adaptive and robust. The intersection point of the two component distributions was
used and is referred to as the Q-intersection threshold (QIT), which is indicated
with vertical dashed lines in Figure 3.1. The distribution of the minimum quality
scores of the codons and hence the QIT varies between different runs for the same
sample, confirming the need for an adaptive filtering strategy.
3.2.3 Filtering of codon tables
Once the QIT is determined, an updated codon table can be constructed. By default
the reads will be trimmed and all codons with a minimum quality score below the
threshold will be filtered from the analysis. The influence of trimming is negligible
as it mainly affects low-quality nucleotides, which are removed by the filter any-
way. The three-step analysis returns a codon table with different variants and their
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Figure 3.1: Distribution of the minimum quality scores of the codons present in a HCV
sample which was sequenced twice in the same run (run1) but in different lanes (lane 1 and
2), and which was sequenced yet another time in another run (run2). The black line shows
the overall fit of the mixture distribution, which consists of the blue, the red and the green
component distributions. The blue and the red distributions correspond to codons that
likely result from sequencing errors, and the green distribution represents reliable calls.
The quality intersection threshold (QIT) is indicated with a vertical black dashed line.
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frequencies at each codon position of the reference, which is robust to sequencing
errors.
3.3 Results
3.3.1 HCV plasmids mixtures
To assess the filtering accuracy of Q-cpileup, we made use of two plasmids that
carry HCV NS3 amino acids 1 to 181 and that differ at only two codon positions,
36 and 155. The two plasmids were mixed in four different proportions – 1:10,
1:50, 1:100 and 1:200 – and sequenced with average coverages of 96,211, 81,179,
95,590 and 74,820 respectively. (see Chapter 2 for sample preparation; sequenc-
ing data are available at the European Nucleotide Archive, accession number PR-
JEB5028). A minor variant is defined as a codon that differs from the consensus.
Hence, only two minor variants are expected at codon positions 36 [GTC (consen-
sus)→ ATG] and 155 [CGG (consensus)→ AAA]; all others can be considered
as false-positive findings. For each of the four sequenced mixes, the QIT was
determined (Table 3.2). Comparison of the number of variants when no filtering
but trimming (QIT=0) is applied and after Q-cpileup reveals that adaptive quality
filtering can reduce the number of false-positive findings by 20% to 50% (third
and fourth columns of Table 3.2). With Q-cpileup, no false-positive findings are
reported with frequencies above 1%, a reporting limit defined in chapter 2. This is
in strong contrast with the 7% to 12% FDR without filtering, for discoveries with
frequencies above 1%. Q-cpileup is able to reduce the number of false-positive
findings while the frequencies of the true minor variants (last columns of Table
3.2) remain unaltered.
The results for the mixing proportion of 1% are shown in more detail in Figure
3.2. A QIT of 19 was used for filtering in this sample (Figure 3.2a). In panel b,
the codons equal to the consensus (called major variants) are investigated before
(QIT=0) and after filtering (QIT=19). The plasmid data have only two real vari-
ants, meaning that the codons investigated here should have frequencies close to
100%. After applying Q-cpileup, the frequencies of the codons are indeed closer
to 100, indicating again that the number of false-positive findings is reduced. The
minor variants are compared in panel c. Without filtering, several minor variants
are reported with frequencies above the reporting limit of 1%. Their frequencies
are strongly reduced after filtering, while the estimates of the true minor variant
frequencies remain (red triangles). This suggests again that quality score filter-
ing provides effective noise reduction while still retaining the reliable calls at low
frequency. Figure 3.2c reveals that our new filtering method allows for lowering
the reporting limit, although the discovery of true variants below 0.5% remains
challenging.
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Figure 3.2: a) Distribution of the minimum quality scores of the codons present in the HCV
plasmids mixed 1:100. The black line shows the overall fit of the mixture distribution,
which consists of the blue, the red and the green component distributions. The blue and the
red distributions correspond to codons that likely result from sequencing errors, and the
green distribution represents reliable calls. The quality intersection threshold (QIT=19) is
indicated with a vertical black dashed line. b) Boxplot of the major variant frequencies
when no filtering is applied (QIT=0) and after Q-cpileup with QIT=19. c) Scatterplot of
minor variants (frequencies before filtering (QIT=0) on the X-axis and after Q-cpileup on
the Y-axis). The true minor variants at codon positions 36 and 155 are indicated with red
triangles, all others can be regarded as false-positive findings. The 1% reporting limit is
indicated with dotted lines.
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Mix QIT N◦ Variants FDR (%)
no filtering Q-cpileup no filtering Q-cpileup
1:10 20 22,405 10,583 12 0
1:50 20 12,724 10,488 7 0
1:100 19 14,886 10,631 6 0
1:200 19 15,692 10,813 8 0
Mix Freq Codon 36 (%) Freq Codon 155 (%)
no filtering Q-cpileup no filtering Q-cpileup
1:10 10.4 11.6 10.3 11.6
1:50 2.28 2.37 2.25 2.37
1:100 0.97 1.00 0.91 0.95
1:200 0.50 0.49 0.43 0.45
Table 3.2: HCV plasmids results for 181 codon positions sequenced with average depth of
87000. For each of four mixing proportions, the QIT is reported that was used for filtering.
The number of reported codons, the false discovery rate for discoveries with frequency
above 1% and the estimated frequencies of the true variants are compared before filtering
is applied and after Q-cpileup.
3.3.2 Comparison with LoFreq, V-Phaser 2 and ShoRAH
The performance of Q-cpileup is compared with three other methodologies: LoFreq
(v0.5.0) [47], V-phaser 2 (v2.0) [44] and ShoRAH (v0.8) [45]. They were run in
their default settings and using the previously described plasmid mixtures. With
ShoRAH, we were unable to use the original bam file, as unresolvable problems
(even after discussion with the developers) were encountered when extracting the
reads from the desired region. Therefore, the ShoRAH results are based on a bam
file with remapped reads against the reference region of interest. None of the ex-
isting methods calls variants immediately at the codon level. Hence, three SNP
callers were chosen based on their capabilities for inferring diversity within vi-
ral populations. The two codon variant positions present in the mixtures differ
at five nucleotide positions, which should be discovered by the SNP callers. The
results are presented in the top part of Table 3.3. None of the methods could dis-
cover the five SNPs at the 0.5% level, and only LoFreq could retrieve all SNPs
present at 1%. Hence, LoFreq is the most sensitive SNP caller in this comparison,
but it also detects some false-positive findings with frequency above 1% (bottom
rows of Table 3.3). Comparison with Table 3.2 reveals that the sensitivity and
specificity for discoveries above 1% with Q-cpileup is outstanding. Especially its
sensitivity is of utmost importance: the method is initially developed for finding
resistance-associated mutations and missing important variants might mislead fur-
ther treatment.
3-10 CHAPTER 3
LoFreq V-Phaser 2 ShoRAH
SNP (WT) 1:200 1:100 1:50 1:200 1:100 1:50 1:200 1:100 1:50
A (G) / 1.03 2.41 0.59 1.06 2.37 / / 2.22
G (C) 0.54 1.01 2.38 / 0.94 2.33 / / 2.22
A (C) 0.66 1.03 2.16 / / / 0.44* 0.80* 1.78*
A (G) 0.48 0.91 2.10 0.52 1.04 2.11 0.44* 0.80* 1.78*
A (G) / 0.89 2.05 0.48 / 2.07 / / 1.28
FDR (%) 0.18 0.18 0.18 0 0.18 0 0 0 0
N◦ 549 553 550 565 578 571 549 546 549
Table 3.3: Frequency estimates of the 5 SNPs present in the mixture of plasmids with
mixing proportions 1:200, 1:100 and 1:50. The first two variants are located in codon 36,
while the others from the codon 155. When the actual variant was not discovered it is
denoted with /. In case of ShoRAH, the frequency is estimated from three overlapping
windows, but often the SNP is only retrieved in two out of the three windows (denoted with
*). The bottom rows of the table report the number of codons detected in the NS3 region
which in theory should be 548 (543 WT + 5 SNPs). The number of false discoveries with
frequencies above 1% is expressed using the false discovery rate calculated as the number
of false discoveries with frequencies above 1% divided by the total number of discoveries
with frequency above 1%.
3.3.3 Clinical HCV sample and comparison with 454
Subsequently, Q-cpileup was applied on a clinical HCV sample (see Chapter 2 for
sample preparation). The fit of the mixture distribution returned a QIT of 26 (Fig-
ure 3.3a). In Figure 3.3b the frequencies of the codons before and after filtering
were plotted on the log scale, which allows a better comparison of low-frequency
variants. The frequencies of the variants that were removed after filtering were
indicated in gray at the bottom. As the truth is unknown in clinical samples one
cannot reliably separate true variants from sequencing errors. However, one could
compare the discovered variants with 454 sequencing results. As 454 sequencing
chemistry is different, another error profile can be expected. Hence, variants that
were not discovered with 454 are more likely to be Illumina sequencing errors (and
vice versa) and are indicated with red triangles in Figure 3.3b. A good correlation
between the filtered and the unfiltered variant frequencies is observed above 1% .
The variants that were not detected in the 454 experiment, likely to be false dis-
coveries, drop in frequency after applying Q-cpileup. Hence, our approach seems
to control the false discovery rate at a reasonable level up to variant frequencies of
0.5%. A lower coverage depth of the 454 experiment did not allow for comparing
Illumina and 454 sequencing for frequencies below 0.1%.
3.3.4 Effect of inter-/intra-run variability on QIT
An equimolar pool of 42 clinical HCV samples was sequenced three times to in-
vestigate the variability in sequencing quality and hence the variability of the QIT.
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Figure 3.3: a) Distribution of the minimum quality scores of the codons present in a HCV
clinical sample. The black line shows the overall fit of the mixture distribution, which
consists of the blue, the red and the green component distributions. The blue and the red
distributions correspond to codons that likely result from sequencing errors, and the green
distribution represents reliable calls. The quality intersection threshold is indicated with a
vertical black dashed line. b) Scatterplot of estimated codon frequencies before (QIT=0)
and after filtering (QIT=26) on the x-axis and y-axis, respectively. The reporting limit of
1% and 0.5% are indicated with dashed lines and dotted lines, respectively. The codons
that were not reported after Q-cpileup are indicated in gray at the bottom. Codons not
detected with 454 sequencing were indicated with red triangles and are likely to be
false-positive findings.
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The 42 samples were sequenced twice within the same run (R1) but on two differ-
ent lanes (L1 and L2), and they were all sequenced again in another run (R2 L3).
For one of these samples, the mixture distribution of each of the three sequencing
runs is shown in Figure 3.1. A clear difference in quality between the runs is ob-
served, resulting in different QITs. Boxplots of the QITs of 42 samples for each
of the sequencing runs show that the inter-run variability of the QIT is larger than
the variability between lanes of the same run (Figure 3.4).
First, the effect of the intra-run variability of the QITs on the final codon table
was investigated. The number of reported codons, with frequency above 1% is
plotted for both lanes in Figure 3.5a. In all, 74% of the samples report at most one
additional codon, depending on the lane on which it is sequenced. The maximum
difference in reported number of codons is four. We further explored frequency dif-
ferences for all codons. The distribution of the differences in frequency between
the two lanes is plotted for each sample in Figure 3.5b. Overall, the frequencies
are similar with some deviations up to 3%. These maxima, however, are mainly
originating from codons located in a GC-rich region, where a coverage drop is
observed. The sample where the maximum absolute difference is observed (indi-
cated in red) is investigated in detail in Figure 3.5c. The frequencies for all codons
discovered on both lanes are plotted against each other on the log scale. No sub-
stantial differences can be observed above 1% . Finally, the maximum differences,
for each of the 42 samples, are reported on a relative scale in Figure 3.5d. The
sizes of the dots are scaled according to the absolute frequency obtained in lane 1,
which teaches us that most deviations occur for frequencies above 50%. Overall,
the reported variants and their frequencies are comparable on both lanes after ap-
plying Q-cpileup, despite slightly different QITs. This is in strong contrast with
the raw data (see Figure 4 in appendix A). These raw data were only trimmed,
which is partially based on quality scores. Without Q-cpileup the comparison of
the samples sequenced on both lanes reveals that (a) the number of reported vari-
ants differs up to 16 variants, (b) deviations of the frequencies go up to 6% and (c)
even for the variants with frequency above 1%, some clear deviations between the
two lanes can be observed. This suggests that Q-cpileup is able to reduce the num-
ber of false-positive findings while retaining the true signal and that the adaptive
approach is able to account for differences in quality between the lanes.
In the next step, the inter-run variability of the QITs was investigated. The sec-
ond run was a very high-quality run with fewer errors (Figure 3.1 comparing run
1 lane 2 and run 2 lane 3). The overall good quality in run 2 makes the estimation
of the error component of the mixture challenging and results in a large QIT. The
effect of these high QITs on the final codon table was investigated. The number of
reported variants, with frequency above 1%, is again similar even after applying
these high thresholds (Figure 3.6a). In all, 83% of the samples report at most one
additional variant, and only one sample reports four additional variants, which is
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Figure 3.4: Boxplot of the QITs of 42 clinical samples for each of the sequencing runs
denoted by run (R) and lane (L) to investigate inter- and intra-run variability. The black
boxplots are part of the intra-run comparison, while the gray boxplot represents the QITs
of the other run. The inter-run variability is larger compared to the intra-run variability.
again the maximum difference in reported number of variants. The distribution of
the frequency differences remains small overall, but the maximum difference in
frequency as well as the relative change for these maxima rises (Figure 3.6b and
3.6d). But these maxima occur again at rather high frequencies. When focusing
on a particular sample, high QITs seem to have no negative impact on the final
codon table (Figure 3.6c). Despite the questionable working assumption that the
second component separates the error distribution from the distribution of the re-
liable calls, the resulting QITs provide reliable codon tables. Hence, our filtering
approach seems robust to deviations from the working assumption. Q-cpileup is
adaptive and thereby can cope with differences in quality between runs.
3.3.5 Robustness of the method
Approximately 400 samples, from both HCV- and HIV-infected subjects, were
sequenced in seven different runs and analyzed with Q-cpileup. Some examples
of the HCV results are displayed in Figure 3.3 and 3.5. The sequenced amplicons
of HCV samples cover GC-rich regions. It is known that Illumina is error-prone
in these regions [37]. This is reflected in the distribution of the minimum quality
scores where more low values are observed than with amplicons of HIV samples
for which no GC-rich regions were covered (Appendix A, Figure 5). It is especially
in these GC-rich regions where you expect that false-positive findings exist with
frequencies above 1% as seen in Figure 3.3b on the x-axis. When applying Q-
cpileup, the frequencies of these false-positive findings could be reduced. In Figure
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Figure 3.5: Effect of the intra-run variability of the QITs on the final reported codon
frequencies. a) Plot of the number of codons with a frequency greater than 1% for the 42
samples sequenced on lane 1 (x-axis) and lane 2 (y-axis). The plotting symbols indicate
the number of codons that differ between the two lanes. b) Boxplots of differences in codon
frequency between two lanes for each of the 42 samples. For each of the samples, 75% of
the codons show differences in frequencies close to zero, while the upper whiskers range
roughly between 0.5% and 3% difference in reported codon frequency, depending on the
lane where the sample was sequenced. c) Comparison of all codon frequencies on the log
scale between two lanes for the sample where the maximum frequency difference is
observed. The frequencies of codons not present in the other lane are plotted in gray. d)
Relative change for codons with maximum absolute difference plotted for each sample.
The relative change is calculated [x1-x2]/x2 with x1 and x2 the codon frequencies for lane
1 and lane 2 respectively (Sample with the maximum absolute difference in red). The sizes
of the dots are scaled according to the estimated frequency in lane 1, indicating that most
maximum differences occur at higher frequencies.
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Figure 3.6: Effect of the inter-run variability of the QITs on the final reported codon
frequencies. a) Plot of the number of codons with a frequency greater than 1% for the 42
samples sequenced on run 1 lane 2 (x-axis) and on run 2 lane 3 (y-axis). The plotting
symbols indicate the number of codons that differ between the two lanes. b) Boxplots of
differences in codon frequency between two runs for each of the 42 samples. For each
sample, 75% of the codons show differences in frequencies close to zero, while the upper
whiskers range roughly between 1% and 5% difference in reported codon frequency,
depending on the run where the sample was sequenced. c) Comparison of all codon
frequencies on the log scale between the two runs for the sample where the maximum
frequency difference is observed. The frequencies of variants that are absent in the other
run are plotted in gray. d) Relative change for codons with maximum absolute frequency
difference plotted for each sample and scaled according to the estimated frequency in
condition 2. The relative change is calculated as [x2-x3]/x3 with x2 and x3 the codon
frequencies for run 1 lane 2 and run 2 lane 3 respectively (sample with maximum
difference is indicated in red).The sizes of the dots are scaled according to the estimated
frequency in run 1, indicating that most maximum differences occur at higher frequencies.
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5 of appendix A, we illustrate that the proposed strategy also similarly reduces the
noise for HIV samples.
Although this new variant calling tool was primarily developed based on Illu-
mina’s GAIIx sequencing data, it can also be a valuable tool for other Illumina se-
quencing platforms such as HiSeq. HiSeq uses the same sequencing-by-synthesis
technique and suffers from the same error types [61]. HiSeq data, analyzed with
Q-cpileup, are presented in Figure 6 in appendix A. The tool, however, is not appli-
cable for pyrosequencing techniques, such as Roche 454. Their quality scores do
not reflect substitution error probabilities but probabilities of calling homopoly-
mers of particular length [46]. For these types of data, the tool can, however,
still generate a codon table, but no threshold determination or QIT-based filtering
should be applied.
3.4 Discussion
Many sequence variant identification tools have been described in literature to call
variants at the SNP level. Most approaches are tailored to call SNPs in human
resequencing projects [40] where SNPs can be either heterologous (50%) or ho-
mologous (100%). However, in viral deep sequencing projects, the SNP frequency
can vary between 100% and 0%, whereas SNPs present in less than 1% of the reads
also may be of interest. Further, our main focus is the detection of drug-resistant
variants for which a specific drug-target region has to be investigated. Hence, it
would be beneficial to report variants at the codon level per amino acid position to
enable an immediate biological interpretation of the variants with respect to their
antiviral drug responses. Variant calling tools used by the virologists in this re-
search field are either not fully described in-house tools [62] or build based on
SNPs [63] at the DNA or RNA level only. In the latter case one needs to retrieve
the linkage information between the neighboring nucleotides to deduce effects at
the coded amino acid level. This process is not always straightforward. Some of
the variant callers developed for viral population sequencing have add-on tools,
like V-profiler [58] for V-phaser [44], to convert the list of SNPs to a list of codon
variants. However, these are mainly developed for 454 data. None of the available
tools reports the variants immediately at the codon level. Therefore, Q-cpileup
was initially developed and imbedded in a pipeline. By taking the weakest link as
a representative for the quality of the codon, the filtering remains at the individual
nucleotide level but reporting is done at the codon level. The approach is adaptive
to allow for differences in quality between the runs.
The intersection point between the distributions of the errors and reliable calls
is suggested as a threshold (QIT). However, other criteria could also be considered.
For instance, the number of false discoveries can be controlled by defining the QIT
as a certain quantile of the reliable call component distribution. By using the 5%
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quantile as a QIT, 5% of the codons, which are truly present in the population, are
falsely considered as being errors. Note that this statement relies heavily on the
interpretation of the distributions as errors and reliable calls. However, the three-
component mixture distribution should be considered only as a working assump-
tion. Moreover, it is impossible to check the actual interpretation of the mixture
distributions. Hence, the interpretation of the different components as error and
reliable calls cannot always be warranted, particularly when low quality scores are
underrepresented. Therefore, we advise users to assess the distribution plots as di-
agnostic tools to critically judge whether the chosen threshold is acceptable and/or
meaningful.
Instead of applying hard filtering with a QIT, as suggested in this chapter, the
posterior probabilities of the reliable call distribution could be used. The counts of
a codon at a particular position can be weighted with these probabilities. By doing
so, codons with a low quality score will have a low contribution in the final fre-
quency estimates. Hence, data are not filtered but weighted with the probabilities
of being truly present in the reliable codon population. This method also relies on
the interpretation of the different component distributions as error distribution and
reliable call distribution.
Importantly, we have shown that the filtering strategy using hard threshold QIT
is robust to runs where the distributions deviate from the working assumption. The
impact on the final codon table frequencies was minimal. Overall, our proposed
filtering strategy controls the false-positive rate at reasonable levels with no false
discoveries above a reporting limit of 1%. The noise is effectively reduced while
retaining the reliable calls even at low frequency. This suggests that the reporting
limit of detection at 1% could be lowered, although distinguishing true variants
from error at 0.5% remains challenging. Depending on the risk one is willing to
take to include a small number of false-positive findings, either one of the cut-
offs can be used. More importantly, Q-cPileup shows a splendid sensitivity that
could not be achieved by the SNP callers while maintaining a good specificity for
variants with frequencies down to 0.5%. This sensitivity will allow further investi-
gation of the reported variants above one of the cutoffs defined by the specificity to
search for resistance-associated mutations, or in the next step to monitor drug resis-
tance and guide treatment [55]. Currently the clinical cutoff is not yet defined for
minority drug-resistant virus variants, and it is still a subject of open debate [65].
Some studies have found no significant association between the presence of low-
frequency variants and subsequent virological failure, whereas others report clear
correlations [68]. The availability of methods that detect low-frequency variants at
the codon level with high sensitivity and good specificity can help in defining the
clinical benefit of low-frequency resistance testing.
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3.5 Conclusion
A variant calling tool is proposed for identifying true variants at the codon level
within a viral population using Illumina sequencing. The variants are filtered using
base-calling quality scores for reducing false-positive findings. The lowest qual-
ity score of the three nucleotides of the codon is taken as representative for the
codon. An adaptive strategy is developed to provide an optimized threshold for
individual samples in each sequencing run. The intersection point of the compo-
nent distributions of the mixture is suggested as a valuable threshold, QIT. Codons
with a quality score below this threshold are not reported. The robustness against
deviations of the working assumption justifies the utilities of our method for low-
and high-quality sequencing runs. It is shown that the generated filtered codon
table is reporting far fewer false-positive findings compared with the codon table
based on the raw data. Moreover, VirVarSeq has a superb sensitivity compared
with existing SNP callers while maintaining a good specificity for codon variants
with frequencies down to 0.5%. This suggests that the current reporting limit of
detection at 1% can even be lowered. The tool is implemented in a user friendly
open-source pipeline, VirVarSeq, which allows virologists to call variants at the
codon level starting from the fastq files.
Acknowledgement
The authors wish to thank the scientists at Janssen Pharmaceuticals who collected
and produced the data as well as Tobias Verbeke and Joris Meys who gave the
necessary IT support. Herwig Van Marck is kindly acknowledged for the insightful
discussions. We are grateful to Prof McLachlan and his team for providing the
original Fortran code and for giving support to write the R-wrapper. Thanks to
Osvaldo, developer of ShoRAH, who was always very helpful when problems
were encountered while running ShoRAH.
4
Model Based Clustering
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Abstract Deep-sequencing allows for an in-depth characterization of se-
quence variation in complex populations. However, technology associated errors
may impede a powerful assessment of low-frequency mutations. Fortunately, base
calls are complemented with quality scores which are derived from a quadruplet
of intensities, one channel for each nucleotide type for Illumina sequencing. The
highest intensity of the four channels determines the base that is called. Mismatch
bases can often be corrected by the second best base, i.e. the base with the sec-
ond highest intensity in the quadruplet. A virus variant model-based clustering
method, ViVaMBC, is presented that explores the quality scores and second best
base calls for identifying and quantifying viral variants. ViVaMBC is optimized to
call variants at the codon level (nucleotide triplets) which enables immediate bio-
logical interpretation of the variants with respect to their antiviral drug responses.
Using mixtures of HCV plasmids we show that our method accurately estimates
frequencies down to 0.5%. The estimates are unbiased when average coverages
of 25,000 are reached. A comparison with the SNP-callers V-Phaser2, ShoRAH,
and LoFreq shows that ViVaMBC has a superb sensitivity and specificity for vari-
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ants with frequencies above 0.4%. Unlike the competitors, ViVaMBC reports a
higher number of false-positive findings with frequencies below 0.4% which might
partially originate from picking up artificial variants introduced by errors in the
sample and library preparation step. ViVaMBC is the first method to call viral
variants directly at the codon level. The strength of the approach lies in the mod-
eling of the error probabilities based on the quality scores. Although the use of
second best base calls appeared very promising in our data exploration phase,
their utility was limited. They provided a slight increase in the sensitivity, which
however does not warrant the additional computational cost of running the offline
base caller. Apparently a lot of the information is already contained in the quality
scores enabling the model based clustering procedure to adjust the majority of the
sequencing errors that are correctly called by the second best base. Overall the
sensitivity of ViVaMBC is such that the technical constraints like PCR errors start
to form the bottleneck for low frequency variant detection.
4.1 Background
In a virology research environment, the study of viral quasispecies in infected pa-
tients is essential for understanding pathways to resistance and can substantially
improve treatment. Genotypic and phenotypic methods are commonly used for
detecting antiviral resistance in clinical HIV-1 and HCV specimens. Standard
genotyping such as direct PCR sequencing methods, however, only provides in-
formation on the most abundant sequence variants. Modern massively parallel
sequencing (MPS) technologies, on the contrary, have the opportunity to allow in-
depth characterization of sequence variation in more complex populations, includ-
ing low-frequency viral strains. However, one of the challenges in the detection of
low-frequency viral strains concerns the errors introduced during the sequencing
process. As these specific errors may occur at equal or even higher frequencies
than true biological mutations, a powerful assessment of low-frequency virus mu-
tations is seriously jeopardized [37, 52].
Many proposals have been made to address this challenge of decreased de-
tection power. Several authors compared the distribution of variants to Poisson,
binomial or beta-binomial error distributions [45, 110–113]. They all, however,
assume that base calls are of equal quality which is not the case in MPS [37, 114].
As a potential solution other authors suggested to incorporate quality scores when
modeling the error distribution [43, 44, 47, 48]. Many of these methods focus pri-
marily on 454 data [43–45, 111–113]. The announcement by Roche to fade out
the 454 technology by mid 2016, illustrates the pressing need to focus on alter-
native technologies [115]. Moreover, the incorporation of quality scores is most
appropriate for Illumina sequencing data. Illumina quality scores reflect the base
calling substitution error probabilities [56], whereas 454 quality scores do not have
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such an intuitive interpretation [46]: they represent the probability of calling a ho-
mopolymer up to a particular length.
Illumina’s sequencing technology is a sequencing by synthesis technology
where the DNA fragments are synthesized one base at a time. The DNA fragments
to be sequenced are first spatially separated and amplified, resulting in clusters of
identical sequences on the sequencing flow cell. Identification of different bases
in the sequencing-by-synthesis process is enabled by using distinct fluorophores
for each nucleotide type (A,C,T,G). At every sequencing cycle a single labeled
3’-blocked nucleotide is incorporated to the complementary strand of each DNA
fragment. The fluorophore is determined with imaging technology using four dif-
ferent fluorescence channels, one for each nucleotide type. For every fragment in
each cycle, the base caller assigns the nucleotide that corresponds with the highest
intensity among the four channels. A correct base identification is complicated
by multiple effects. On the one hand, emission spectra of the fluorophores are
overlapping, especially the A and C intensities and the G and T intensities. On
the other hand, phasing and pre-phasing describes the loss of synchrony of the
sequence copies of a cluster. Phasing is caused by incomplete removal of the
3′-protecting groups resulting in sequences within clusters lagging behind in the
incorporation cycle. Pre-phasing is caused by the incorporation of nucleotides
without effective 3′-protecting groups. This can cause incorporation of multiple
bases in each cycle and might hamper a correct interpretation of the intensities.
Quality scores are derived from the intensities [35]. From literature [116] and own
experiments it is clear that these quality scores often underestimate the true error
probabilities. Extra information which can be used in this context is the second
best base calls, which are the bases corresponding to the second highest intensity.
Abnizova et al. [50] observed that a mismatch base could often be corrected by its
second best base call. In an experiment with known reference sequence 722,505
codons were evaluated of which 34,644 were errors (≈5%). Seventy percent of
these errors could be corrected by the second best base calls (see later for more
details). Hence, we will explore the utility of second best base calls in addition to
the quality scores within a new variant calling algorithm.
Here we propose Virus Variant Model-Based Clustering (ViVaMBC), a method
that models error probabilities of the best and second best base calls as a function
of the Illumina quality scores. These error probabilities are embedded in a multi-
nomial mixture so that viral variants can be identified and quantified. This chapter
will illustrate and validate this method using read sets with known variation and
evaluate the minimum sequencing depth. Its performance will be empirically com-
pared with three other methods (LoFreq [47], V-Phaser2 [48] and ShoRAh [45]).
Finally, we will demonstrate ViVaMBC on a clinical HCV sample.
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4.2 Methods
4.2.1 Experiments
A sample from an HCV-infected patient as well as HCV plasmids were paired-end
sequenced using Illumina’s genome analyzer(GA)IIx according to manufacturing
protocols. A detailed description of the data and protocols is given in chapter
2. The sequencing images are converted into reads using Illumina’s off-line base
caller (OLB) [117]. In contrast to the standard workflow, using real time analy-
sis (RTA), the OLB can also provide second best base calls which are explored
for an improved error correction. In the next steps reads are aligned against a
consensus sequence using BWA [59]. The resulting bam files are adapted using
GATK clipReads to revert the trimming of the data performed by the aligner, and
all reads containing indel errors are removed (workflow presented in Appendix C).
It is hereby assumed that indels will result in non-viable viruses. These bam files
are used as input of ViVaMBC which is explained in the next section.
4.2.2 Model-based clustering
Let ri denote the vector with the best base calls of read i, with i ranging from 1 to
n. Similarly, si denotes the vector with the second best base calls of read i. The
vector with the corresponding error probabilities is denoted as θri and θsi for best
and second best base calls respectively. A dummy variable Pairi is introduced to
indicate which end of the DNA segment is sequenced in the paired-end sequencing
strategy: Pairi equals 1 if read i is first in pair and 0 otherwise. In case of single-
end experiments the variable Pairi can simply be omitted from the model. The
library of reads represent the whole viral population consisting of several viral
subspecies.
The variant calling is applied locally. Upon read alignment the vectors ri are
retained that cover a small window of the reference sequence under investiga-
tion. To avoid the challenges involved in inferring haplotypes [66], only windows
smaller than the actual read length are considered. Let m denote the length of the
window; thus rti = (ri1, . . . , rim), APi denote the average quality score of read
i in window m and θoil with l = (1, . . . ,m) denotes the probability that the lth
nucleotide from read i differs from ril or sil. Typically in our application m = 3
to call variants at codon level, nucleotide triplets. ViVaMBC will be a SNP caller
when m = 1.
Suppose that k variants of length m exist with variant sequences given by the
vectors h1, . . . ,hk. Let τj denote the prior probability that a read originates from
variant j (j = 1, . . . , k). They have the interpretation of relative frequencies of the
viral variants within the window, which are the key parameters of interest inferred
from the observed data.
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The likelihood of the observed data has the natural interpretation of a mixture
model with k components that refer to the true variants. The likelihood is the
product of the probabilities that a read was generated from the mixture of variants
with relative frequencies τj :
L =
n∏
i=1
f(ri, si) =
n∏
i=1
 k∑
j=1
τjfj(ri, si)
 , (4.1)
where f denotes a generic density function and fj is the probability of observ-
ing best calls ri and second best calls si when read i belongs to variant j. Upon
relying on the multinomial distribution, the probability fj can be written as
fj(ri, si) =
m∏
l=1
fj(ril, sil) =
m∏
l=1
θ
I(ril=hjl)
ril θ
I(sil=hjl)
sil θ
(1−I(ril=hjl))(1−I(sil=hjl))
oil ,
(4.2)
in which I(A) = 1 if A is true, and I(A) = 0 otherwise. Note, however,
that the probabilities θril, θsil and θoil can not be estimated from the data because
the model is over-identified (two parameters for each observation). We therefore
model the θ parameters as a function of the quality scores of the best base calls
(Pril), a dummy variable Pair (Pairi ), and the average quality score (APi). For
each location l, the θ’s refer to a multinomial distribution with three classes for
which we suggest a multinomial logit model
log
θcil
θoil
= β0c + β1cPril + β2cPairi + β3cAPi, (4.3)
with c ∈ {r, s}. For paired-end experiments eight β parameters need to be
estimated together with the variant sequences hj (j = 1, . . . , k) and the relative
frequencies τj . For single-end experiments two β parameters are removed since
the Pairi variable can be omitted. To infer the true variants and their frequencies
the log likelihood
l =
n∑
i=1
log
 k∑
j=1
(
τj
m∏
l=1
θ
I(ril=hjl)
ril θ
I(sil=hjl)
sil θ
(1−I(ril=hjl))(1−I(sil=hjl))
oil
) ,
(4.4)
after substituting the θ-parameters with (4.3) will be maximized. However,
as closed form solutions for τj , hj and β are not available, numerical methods
were implemented for direct maximization of the log likelihood (4.4). The EM
algorithm is a popular alternative for maximizing mixture distributions [118,119].
It requires the introduction of latent or ’missing’ indicator variables zij which are 1
when read i belongs to variant j and zero otherwise. Note that zi = (zi1, . . . , zik)t
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are multinomial distributed with density g(zi) and P (zij = 1) = τj . Hence the
likelihood (4.1) can be augmented
L =
n∏
i=1
f(ri, si, zi) =
n∏
i=1
f(ri, si|zi)g(zi) =
n∏
i=1
k∏
j=1
(fj(ri, si)τj)
zij , (4.5)
which in turn allows an efficient factorization by conditioning on zi. In par-
ticular, given I(r)ijl = I(ril = hjl) and I
(s)
ijl = I(sil = hjl), the complete data
log-likelihood lc can be written as
lc =
n∑
i=1
k∑
j=1
zij
{
log τj
+
m∑
l=1
[
I
(r)
ijl log θril + I
(s)
ijl log θsil + (1− I(r)ijl )(1− I(s)ijl ) log θoil
]}
, (4.6)
in which the θ parameters have to be substituted with (4.3). The EM algorithm
iterates over an expectation (E) and a maximization (M) step until convergence.
1. E step: Computation of the expected complete data log-likelihood (4.6),
given the observed data and the current parameter estimates. The solution is
given by (4.6) with zij replaced by
ẑij = E(zij | ri, si) = τ̂jfj(ri, si|ĥj , β̂)∑k
l=1 τ̂lfl(ri, si|ĥj , β̂)
(4.7)
where fj depends on ĥj and the β̂ parameter estimates from the previous
M-step.
2. M step: Maximization of the expected complete data log-likelihood from
the E-step with respect to τ , h, and β parameters. This results in updated
parameter estimates. In particular
• τj is estimated as
τ̂j =
∑n
i=1 ẑij
n
(4.8)
• hj is the most abundant sequence among those with maximal ẑij across
the variants (j = 1, . . . , k).
• β parameter estimates are obtained by fitting the multinomial regres-
sion model (4.3) using the ẑij as weights.
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The EM algorithm is initialized with k variants (as a default k is set to 10).
The kth most observed variants are taken as initial variant sequences hj (j =
1, . . . , k). These variants are updated in each M-step. A variant j will disappear if
no sequences are attributed to cluster j. Upon convergence, the number of variants
k and their final estimates of τj and hj define the variant population in the window
of size m.
The method is optimized for window size m = 3 to retain linkage informa-
tion between single-nucleotide polymorphisms. These nucleotide triplets (codons)
facilitate the biological interpretation in the coding regions of the virus. Since
resistance-associated mutations against antiviral drugs are particularly of interest,
drug-target regions within viral protein coding regions will be investigated. Hence,
the reported codon variants can be interpreted immediately with respect to their
antiviral drug responses. ViVaMBC is implemented in R and parallelized. Each
window of interest can be run on a different core, thereby speeding up the per-
formance. Approximately, one position runs for 1 hour when coverages around
60,000 are reached and m = 3. More information can be found in Appendix C.
4.3 Results
In the following sections, first the sensitivity and specificity of ViVaMBC with
m = 3 will be investigated using read sets with known variation. Subsequently,
the minimum depth of coverage needed for unbiased estimates will be defined and
its overall performance will be compared with three SNP-callers LoFreq [47], V-
Phaser2 [48], and ShoRAH [45]. Finally,ViVaMBC will be illustrated on a clinical
HCV sample where the NS3 region will be investigated to search for resistance
associated mutations against NS3-4A serine protease inhibitors, telaprevir, and
boceprevir [73].
4.3.1 Sensitivity and specificity
Two different plasmids carrying HCV NS3 amino acids 1 to 181 were mixed in
four different proportions. These plasmids differ only at codon positions 36 and
155. The mixing proportions were 1:10, 1:50, 1:100, and 1:200 (fastq files are
available at the European Nucleotide Archive, accession number PRJEB5028, see
chapter 2 for sample preparation). The mixtures were sequenced at an average cov-
erage of 86,000. The plasmid mixture enables the quantification of true positives
(variants at the two codon positions) and the assessment of the amount of errors
that could be corrected by second best base calls (see Appendix C). The sensitivity
of ViVaMBC was quantified using the two variant positions. The estimated fre-
quencies, τj , of the real variants at codon positions 36 and 155 were close to the
mixing proportions (Table 4.1), suggesting that frequencies down to 0.5% can be
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reliably estimated. Codons for the first 181 aminoacids of the NS3 region were
called to investigate the specificity. No other variants are expected in this region
besides the two variant positions, and hence only the wild type codons (with fre-
quencies close to 100%) and the two variants should be detected. The number of
codons reported by ViVaMBC were compared with the number of codons present
in the raw data. In analogy with mpileup for SNP calling, a pileup table is built
at the codon level where the low-quality parts of the reads are removed prior to
the pileup, called trimming (see Appendix C for more details). The comparison
with such a pileup table allows to assess the number of false-positive findings that
are actually removed by ViVaMBC. The pileup resulted in far more than 10,000
codons while ViVaMBC detected only 599 to 841 codons in the same region (Table
4.2). This indicates that ViVaMBC removes the vast majority of false-positive find-
ings. From the reported codons we removed the wild type codons with frequencies
close to 100% together with the two variants and investigated the frequencies of
the remaining false-positive findings. The maximum frequency of these errors is
above 1% for the pileup and drops below 1% for ViVaMBC. The frequency distri-
bution of the errors is presented in Appendix C Figure 4, which shows that the vast
amount of frequencies for false positive variants in ViVaMBC is well below 0.4%.
Some false-positive findings are expected in this frequency range as sample and
library preparation errors are known to occur with frequencies up to 0.25% [107].
While the discovery of codon variants at 0.5% and 1% was hampered in the pileup
table, it could be detected with almost 100% specificity using ViVaMBC. The spe-
cific contribution of the second best base error probabilities in ViVaMBC to these
increased sensitivity and specificity is further explored in appendix 3.
Mix 36 ATG (%) 155 AAA (%)
1:200 0.45 0.42
1:100 0.92 0.91
1:50 2.28 2.20
1:10 11.04 10.01
Table 4.1: Sensitivity of ViVaMBC in plasmid experiment. Two HCV-plasmids which differ
at two codon positions 36 and 155 were combined in a sample for Illumina deep
sequencing at four different mixing proportions. Their frequencies were estimated with
ViVaMBC, which was able to retrieve codon variants with frequencies up to 0.5%.
4.3.2 Minimum depth of coverage
The influence of coverage depth on the accuracy of τ̂j is investigated using the
plasmid data by mixing 1:200 for codon position 155. The original data covered
this position 64,668 times. Datasets with lower coverages are generated by ran-
dom sampling a fraction (f=0.1, 0.2, . . . , 0.8 ,0.9) of the reads from the original
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Pileup ViVaMBC
Mix N◦ Codons max noise N◦ Codons max noise
freq (%) freq (%)
1:200 15,692 1.46 599 0.67
1:100 14,886 1.41 599 0.68
1:50 12,724 1.47 841 0.72
1:10 22,405 1.53 492 0.65
Table 4.2: Specificity of ViVaMBC in plasmid experiment. The number of codons in the
NS3 are reported after pileup and ViVaMBC. Theoretically, 183(181+2) codons are
expected, but far more are reported, especially when piling up the raw data. The maximum
frequency of the false positive codons is presented as well. ViVaMBC is able to reduce
these frequencies below 1% while they reached more than 1% after Pileup. This illustrated
that ViVaMBC is able to reduce drastically the number of false-positive findings and to
lower the detection limit above which 100% specificity is expected.
dataset. Ten datasets were generated for each fraction f resulting in 90 datasets
with average coverages ranging between 6,463 and 58,185.
ViVaMBC reported two codons for the original dataset at codon position 155:
the wild type codon CGG at a frequency of 99.58% and the variant AAA at 0.42%
which is indicated with the green dotted line in Figure 4.1. The frequencies (τj)
of the variants (hj) for this position reported by ViVaMBC for each of the 90
re-sampled datasets are plotted in Figure 4.1. The true codon variant AAA (green
dots) was detected in all datasets. Averages frequency estimates over the 10 repeats
are indicated with green triangles. Figure 4.1 indicates that lower coverages reduce
the precision and increase the bias of the estimates. These deviations start to appear
from fraction 0.4, which corresponds with coverage around 25,000. The number
of false-positive findings also increases when less reads are available, but their
frequency estimates remain far below 0.4% and the variant at 0.5% can still be
discovered at the lowest coverage.
4.3.3 Comparison with other methods
The performance of ViVaMBC is compared with LoFreq (v0.5.0) [47], V-Phaser
2 (v2.0) [48], and ShoRAH (v0.8) [45] (all ran in their default settings) using
the previously described plasmid mixture data. With ShoRAH we were unable to
use the original bam file since some problems were encountered when extracting
the reads from the desired region. Therefore the ShoRAH results are based on a
bam file with remapped reads against the reference region of interest. As none of
the existing methods calls variants immediately at the codon level, the evaluation
is restricted to the ability to detect variants at individual nucleotide level. The
two variant codons differ at 5 nucleotides from the wild type, so 5 SNPs should
be detected. The comparison is made with ViVaMBC at the codon level since
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Figure 4.1: Influence of coverage depth on the estimation of τj . Datasets with lower
coverages are generated by random sampling a fraction (f=0.1, 0.2, . . . , 0.8 ,0.9) of the
reads from the original dataset. Ten datasets were generated for each fraction f resulting
in 90 datasets with average coverages ranging between 6,463 and 58,185. The reported
variants for all re-sampled datasets were plotted and colored according to the discovered
codon. The green dots indicate the true variant and all others are false-positive findings.
The average frequency of the true variant (averaged over the ten random samples) is
indicated with triangles. The dotted line is the true frequency as estimated from the
original dataset. Lowering the coverage increases the bias, the variance of the estimate
and the number of false-positive findings.
these variants can be interpreted immediately with respect to their antiviral drug
responses, which is our primary application domain. The results of ViVaMBC at
the SNP level are reported in Appendix C.
The estimated frequencies of the true SNPs for the mixing proportions 1:200,
1:100, and 1:50 are presented in Table 4.3 for the existing methods. None of them
were able to retrieve all 5 SNPs at a frequency of 0.5%. LoFreq could recover
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them at a frequency of 1% while the others still showed false-negative findings for
the 1:100 mixtures. ViVaMBC, on the other hand, was able to discover both codon
variants at a frequency of 0.5% and above (Table 4.1).
The total number of false discoveries over the whole NS3 region (181 codons
of 3bp long) are reported at the bottom of Table 4.3 together with the maximum
frequency of these false-positive findings. All methods seem to control the total
number of false-positive findings much better than ViVaMBC, but the frequencies
of these false-positive findings are close to 1% or even above and hamper the dis-
covery of true variants with similar frequencies. Despite the higher number of
false-positive findings discovered in ViVaMBC, a clear distinction between true-
and false-positive findings can be made for frequencies around 1%. And with one
exception, all false-positive findings fall below 0.4% (see Figure 4.2). So over-
all ViVaMBC has a higher sensitivity and specificity for the discovery of codon
variants at frequencies above 0.5%.
LoFreq V-Phaser 2 ShoRAH
SNP (WT) 1:200 1:100 1:50 1:200 1:100 1:50 1:200 1:100 1:50
A (G) / 1.03 2.41 0.59 1.06 2.37 / / 2.22
G (C) 0.54 1.01 2.38 / 0.94 2.33 / / 2.22
A (C) 0.66 1.03 2.16 / / / 0.44* 0.80* 1.78*
A (G) 0.48 0.91 2.10 0.52 1.04 2.11 0.44* 0.80* 1.78*
A (G) / 0.89 2.05 0.48 / 2.07 / / 1.28
N◦ fSNP 3 5 2 19 32 24 4 1 1
Max Freq 1.04 1.01 1.02 0.97 1.40 0.72 0.92* 0.5* 0.89
Table 4.3: Sensitivity and specificity of competing methods in plasmid experiment.
Frequency estimates of the true SNPs after applying the algorithms LoFreq, V-Phaser 2
and ShoRAH on the mixture of plasmids mixed at 1:200, 1:100 and 1:50. Two SNPs should
be present in codon 36, while three SNPs are present in codon 155. In case of ShoRAH, the
frequency is estimated from three overlapping windows, but often the variant is detected in
two out of three windows (denoted with *). None of the methods seem to be able to retrieve
all 5 SNPs at 0.5%. The bottom rows of the table report the total number of false SNPs
over the whole NS3 region (543 bp long) together with their maximum frequency. The total
number of false-positive findings is very low for all methods but their frequencies rise close
to 1% which hamper the distinction of true SNPs from this false-positive findings.
4.3.4 Clinical sample
The application of ViVaMBC is illustrated here on a clinical HCV sample for
which the NS3 amino acids 1 to 181 were sequenced with two sequencing plat-
forms (454 and Illumina). The error prone GC-region was used for assessing the
performance of ViVaMBC but we compared here the conclusions of the two plat-
forms on the same sample. As 454 sequencing technology uses a different se-
quencing chemistry (see protocol in chapter 2) it typically results in another error
profile. Variants not discovered with 454 can thus be assumed to originate from
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Figure 4.2: Specificity comparison of ViVaMBC with LoFreq, V-phaser 2 and ShoRAH.
The frequencies of all minor variants discovered in the three mixtures 1:200, 1:100 and
1:50 are plotted for ViVaMBC, LoFreq, V-phaser 2 and ShoRAH. Note that these variants
are at the codon level for ViVaMBC and at the SNP level for the other methods. The false
positive variants are indicated with black dots and the true positives with gray crosses. It
is clear that although far more false-positive findings are discovered with ViVaMBC, the
distinction with the true positives is more apparent.
MODEL BASED CLUSTERING 4-13
Illumina sequencing errors (and vice versa). In Figure 4.3a the estimated frequen-
cies of the codons discovered by ViVaMBC are plotted against the corresponding
frequencies of the pileup. Codons present in only one of the two methods are
plotted in gray on their respective axis. Codons that were not present after piling
up the 454 reads were indicated with triangles. Above 0.5% (dotted lines) a good
correlation is observed between the two estimates. A few codons with frequencies
above 0.5% in the pileup are not reported by ViVaMBC. These codons were also
absent in 454 reads and can be considered as false-positive findings in the pileup.
On the other hand, three codons showed a frequency above 1% with ViVaMBC
while they had a lower frequency in the pileup, one of which was only present in
454. These codons might be false-positive findings called by ViVaMBC, however
since it is a clinical sample, it is difficult to assess. Overall, ViVaMBC has a very
good sensitivity; none of the true variants discovered with Pileup was missing.
The false discovery rate (FDR), calculated as the number of false-positive find-
ings (codons not present in 454) divided by the total number of discovered codons
is investigated for different reporting limits ranging from 0.1% to 1% for both Vi-
VaMBC and pileup (Figure 4.3b). ViVaMBC has much lower FDR compared to
pileup table for all reporting limits under investigation. While the FDR rapidly
increases at low frequencies for the pileup, it remains stable for ViVaMBC up to a
frequency of 0.4% before increasing, which is again in the frequency region where
PCR errors start to occur as well. Moreover, the 454 experiment was limited in its
detection due to the limited depth of coverage.
Additionally, the three methods LoFreq (v0.5.0) [47], V-Phaser 2 (v2.0) [48],
and ShoRAH (v0.8) [45] were ran on the clinical sample. ShoRAH, however,
crashed in the final stage of the analysis while running the snv.py script. Hence,
Figure 4.4 only presents the comparison of the results of ViVaMBC with those
of LoFreq and V-Phaser at SNP level using a barplot representing the number of
reported variants at a particular frequency range. The shaded region in the bars for
ViVaMBC corresponds to the fraction of codons that were also discovered with
454. Each of the codons reported both by ViVaMBC and 454, contains at least one
SNP that should be detected by LoFreq and V-Phaser. V-Phaser, however, reports
fewer variants in the majority of the bins, which indicates that it misses some true
positives even at higher frequencies. LoFreq seems to perform better and detects
all variants up to 1% but is less sensitive at lower frequencies. ViVaMBC prob-
ably reports two false positives in the frequency bin [1% − 5%], these were also
indicated in Figure 4.3a, but our method detects far more true positives especially
in low-frequency ranges as compared to the other methodologies. The results con-
firm that codon variants with frequencies down to 0.5% can be reliably detected
with ViVaMBC and that false positives start to appear at lower frequencies. Even
down to 0.25% the proportion of false positives remains acceptable.
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Figure 4.3: Sensitivity and specificity comparison of ViVaMBC with pileup of a clinical
HCV sample. a) Comparison of the codon frequencies after piling up the data (x-axis) with
the estimated frequencies of ViVaMBC (y-axis). Codons represented with triangles were
absent after 454 sequencing on the same sample and hence assumed to be false-positive
findings. Codons colored in gray are present in either one of the two methods. Frequencies
of 0.5% and 0.25% are indicated with dotted and dashed lines respectively. Above 0.5%
and even above 0.25% a good correlation is observed where a few false-positive findings
are filtered out using ViVaMBC b) False discovery rates for both ViVaMBC and pileup are
calculated with changing reporting limits. The FDR is higher and increases more rapidly
for the pileup.
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Figure 4.4: Comparison of LoFreq and V-Phaser with ViVaMBC on clinical sample.
Barplot represents the number of reported variants (at SNP or codon level) by the different
methodologies for different frequency bins. The bars are colored according to the method.
The shaded region in the bars for ViVaMBC corresponds to the fraction of codons that
were also discovered with 454.
4.4 Discussion
Many SNP calling tools have been described in the literature to correct sequencing
errors. Most approaches are however tailored to call SNPs in human resequenc-
ing projects [40] where SNPs can only be either heterologous (50%) or homolo-
gous (100%). In viral deep sequencing projects, SNPs present in less than 1% of
the reads are often of interest [68] making the correction much more challenging.
Wilm et al. [47], among others, have shown that incorporating quality scores im-
proves sensitivity without loss of specificity. The comparison with existing tools
showed, however, that issues with the detection of low frequency variants with
a frequency below 1% in viral populations remains largely unsolved by the cur-
rently available methods. ViVaMBC embeds quality scores and the second best
base calls within a model-based clustering approach. The method enables an in-
crease in sensitivity for variants with frequencies below 1%, while retaining good
specificity above 0.4%. When no second best base calls are available, ViVaMBC
still shows an improved sensitivity in comparison with the existing methodologies.
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Although the potential of the second best base calls seemed very promising in the
data exploration phase, the additional computational cost of running the offline
base caller is not warranted for our specific application. At frequencies below 0.4%
we start to see errors where some of them are presumed as being incorporated dur-
ing sample and library preparation. These artificial mutations cannot be identified
as errors because the base substitutions are passed to all sequences of the clus-
ter on the flow cell. Hence, these sample and library preparation errors form the
limit for detection since only sequencing errors can be corrected with ViVaMBC.
To obtain excellent sensitivity and specificity, samples need to be sequenced deep
enough. When coverage falls below 25,000 the number of false-positive findings
increases and the frequency estimates become biased. Furthermore, ViVaMBC is
one of the first tools that calls variants at the codon level, which is particularly
of interest in virology applications where drug-target regions are investigated for
resistance-associated amino acid mutations. V-phaser 2 and ShoRAH have add-on
tools, V-profiler [58] (v1.0) and localVariants [120] (version january 8th 2014),
respectively, to convert lists of SNPs to lists of codon variants. LocalVariants is an
unpublished tool which is still under development and until now we were unable
to run it on our data. At this moment, it failed to define the reading frame based on
the number of stop codons. V-Profiler is developed as an add-on tool for V-phaser
and the output of V-phaser 2 must be converted to serve as an input for V-profiler.
Both V-profiler and localVariants primarily focused on 454 data, and only shifted
later to Illumina sequencing. The add-on tools are not fully converted yet, which
makes the translation of the list of SNPs to a list of codon variants not straight-
forward. This illustrates the challenges of retaining linkage information between
neighboring SNPs and the need for variant calling methods at the codon level.
The current version of ViVaMBC assumes that each of the n reads covers the
entire window of m nucleotides. In practice, many reads cover only partially the
window. Although these reads are currently ignored by our method it has a fairly
low impact on the results as variant calling is done at the codon level m = 3. Ig-
noring reads can become problematic when larger window sizes m are of interest,
for instance when investigating co-occurence of mutations in neighboring codons.
If one assumes missingness completely at random, the likelihood approach could
be continued with the observed data only. The method only has to be adapted to
work with unbalanced data; not all reads will have the same length m. Let vil
denote an indicator which is vil = 1 if read i has a call at position l and zero
otherwise. The density fj in (4.1) and (4.2) become
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fj(ri, si) =
m∏
l=1
fj(ril, sil)
vil
=
m∏
l=1
[
θ
I(ril=hjl)
ril θ
I(sil=hjl)
sil θ
(1−I(ril=hjl))(1−I(sil=hjl))
oil
]vil
. (4.9)
Subsequently, the complete data log-likelihood (4.6) becomes
l = logL =
n∑
i=1
k∑
j=1
zij
{
log τj +
m∑
l=1
vil
[
I
(r)
ijl log θril
+I
(s)
ijl log θsil + (1− I(r)ijl )(1− I(s)ijl ) log θoil
]}
. (4.10)
We successfully ran ViVaMBC for a HCV-clinical samples where the whole
NS3 region is assessed. Investigation of the reported codons will help us to dis-
cover mutations associated to resistance against protease inhibitors and to establish
the clinical relevance of resistance associated mutations [121]. While ViVaMBC
is especially developed for virology applications it might be also applicable in
targeted sequencing of cancer associated genes where one wants to uncover the
tumor-population heterogeneity. These targeted cancer panels investigate again
coding regions, hence working at the codon level makes absolutely sense here.
4.5 Conclusion
ViVaMBC is proposed for identifying variants at the codon level within a viral
population using Illumina sequencing. The parameters τj and hj define the local
viral population and are inferred given the observed data. We demonstrated here a
superb sensitivity of ViVaMBC while keeping the frequencies of the false-positive
findings below 0.4% when an average coverage of 25,000 is reached. The strength
of the method lies in modeling the error probabilities, based on the quality scores,
which enables to correct a large fraction of the mismatch bases incorporated during
the sequencing process. When no second best base calls are available, ViVaMBC
can be run without them while it still provides an optimal sensitivity when report-
ing limits of 0.5% are applied. The technical constraints like PCR errors start to
form the bottleneck for low-frequency variant detection.
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5
Discussion and Perspectives
Two different variant callers were presented in chapters three and four. They ap-
proach the challenge of distinguishing noise from low-frequency variants from
another perspective. In the following, the two methods will be compared. The
presented research project was granted by IWT Baekeland. Hence, the economic
finality of the project is important which will be explained in the subsequent sec-
tion. We close by future perspectives and a final conclusion.
5.1 Qualtity based adaptive filtering versus model
based clustering
In contrast to most public available variant callers, the two developed tools, Vir-
VarSeq and ViVaMBC call variants at the codon level which enables immediate bi-
ological interpretation of the variants with respect to their antiviral drug responses.
They approach, however, the challenge of reducing the false-positive findings dur-
ing variant calling from two different viewpoints. VirVarSeq is a pipeline which
reduces the number of false-positive findings by filtering low-quality codons. A
data-driven threshold is defined to account for differences in quality between runs.
On contrary, ViVaMBC keeps all data even the low quality codons and models
the error probabilities of the best and second best base calls by using the quality
scores. These error probabilities are used to divide the codons into clusters. In
the following, both methods will be compared on HCV plasmids and a clinical
sample.
5-2 DISCUSSION AND PERSPECTIVES
5.1.1 HCV plasmids mixtures
Both variant calling methods were applied to the mixture of plasmids that carry
HCV NS3 amino acids 1 to 181 and that differ only at two codon positions, 36 and
155 (see chapter 3 and 4). These plasmids were mixed in four different proportions
–1:10, 1:50, 1:100 and 1:200. The results are brought together and compared
in Table 5.1. Both methodologies find the two variants in the NS3 region with
frequency estimates close to the mixing proportions suggesting that they have both
superb sensitivities. Other methods, as described in chapter 3 and 4 were not able
to find the corresponding SNPs at the lowest frequencies.
Mix VirVarSeq ViVaMBC
QIT Codon 36 Codon 155 Codon 36 Codon 155
1:10 20 11.6 11.6 11.04 10.1
1:50 20 2.37 2.37 2.28 2.20
1:100 19 1.0 0.95 0.92 0.91
1:200 19 0.49 0.45 0.45 0.42
Table 5.1: Estimated frequencies of the variant positions for the different mixing
proportions of the HCV plasmids for both VirVarSeq and ViVaMBC together with the
quality threshold used by VirVarSeq.
All variants, except the spiked-in variant at position 36 and 155, can be con-
sidered as false-positive findings. After quality-based filtering, more than 10,000
false-positive findings remain while ViVaMBC reduces these number to a few hun-
dreds (displayed on the right of Figure 5.1). This means that VirVarSeq reports
almost all possible codons at very low frequencies (64∗181 = 11584). The distri-
bution of the frequency estimates of false-positive findings is shown in Figure 5.1.
The number of outliers for VirVarSeq reaches a thousand, which is more than the
total number of false-positive findings for ViVaMBC. No false-positive findings
remain with frequencies above 1% for neither one of the methods. False-positive
findings start to occur regularly with frequencies around 0.5% for VirVarSeq while
ViVaMBC is able to reduce these frequencies a little bit more. Hence, detection
of low-frequency variants down to 0.5% becomes feasible for ViVaMBC while
keeping very good specificities.
5.1.2 HCV clinical sample
Subsequently the variant calling methods are compared for the genomic region,
coding for amino acid 1 to 181 of NS3 of a HCV clinical sample. Prior to filtering
of the variants called in the sequencing experiment, VirVarSeq requires the deter-
mination of the quality threshold, QIT as described in Chapter 3. Figure 5.2 shows
the distribution of the minimum quality scores of the codons present in the sample
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Figure 5.1: Boxplots of false-positive findings for the different datasets both for VirVarSeq
(black) and ViVaMBC (grey). Number of false-positive findings represented in the boxplots
is displayed at the right.
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Figure 5.2: Distribution of the minimum quality scores of the codons present in the sample
of the whole NS3 region. The black line shows the overall fit of the mixture distribution,
which consists of the blue, the red and the green component distributions. The blue (point
probability at two), and the red component distribution correspond to codons that likely
result from sequencing errors, and the green distribution represents reliable calls. The
quality intersection threshold (QIT) is indicated with a vertical black dashed line.
together with the fit of the mixture distribution. The Q-intersection threshold is 28
which is indicated with a vertical dashed line. Hence, all codons with a minimum
quality score below 28 are filtered and 1943 codons remain for the whole NS3
region.
The alignment after consensus mapping of the VirVarSeq pipeline was used
as a starting point for ViVaMBC. The second best base calls where added and
the model based clustering was applied. ViVaMBC reports only 1390 codons for
the NS3 region which is a reduction of 28% of the number of reported codons
compared to VirVarSeq.
In Figure 5.3 the frequencies of the reported codons are plotted for the model
based clustering and the adaptive filtering on the x-axis and the y-axis respectively.
The codons that are reported by only one method are plotted in gray on the bottom
of the respective axis. It concerns 721 codons for VirVarSeq and 168 codons for
ViVaMBC. Above the reporting limit of 1% the two methodologies are in agree-
DISCUSSION AND PERSPECTIVES 5-5
Figure 5.3: Comparison of the codon frequencies reported by ViVaMBC (x-axis) and by
VirVarSeq (y-axis). Codons that are only reported by ViVaMBC are plotted along the
x-axis in blue, while the ones that are only reported by VirVarSeq are plotted along the
y-axis in gray. Reporting limits of 1% and 0.4% are indicated with dashed lines.
ment. Even up to 0.4%, a reporting limit which was suggested for ViVaMBC, the
reported codons and their frequencies are similar. Only two codons, both in the
GC-rich region which is known to be error-prone, have frequencies that clearly
differ between the two methodologies. Additionally six codons have estimated
frequencies close to 0.4% in ViVaMBC while they were filtered in VirVarSeq.
Since, the methods are applied on a clinical sample it is difficult to judge which
of the two methodologies is more correct. Below 0.4%, the frequency estimates
of the reported codons differ between the two methodologies where in general the
estimates of ViVaMBC are slightly higher.
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5.1.3 Discussion
The two methodologies, VirVarSeq and ViVaMBC, report similar codons when the
reporting limit of 0.5% is applied, although they approach the challenge of distin-
guishing noise from low-frequency variants from another perspective. Below the
reporting limit, VirVarSeq reports probably more false-positive findings compared
to ViVaMBC. In some cases, VirVarSeq reports almost all possible codons. On
the other hand, ViVaMBC might introduce false positive findings in the GC-rich
region, since frequency estimates of variants in these regions seems to be boosted.
Hence, it might be appropriate to add additional parameters in the modeling ap-
proach which account for the GC-context. Further it is difficult or either impossi-
ble to assess if ViVaMBC, while reporting less ultra low-frequency variants, still
detects all reliable variants at these low frequencies. There is most probably a
trade-off between sensitivity and specificity where VirVarSeq is most sensitive,
but less specific. It is very difficult to decide which of the two elements, sensitivity
or specificity, is most important and it might depend on the application. Often,
reporting limits are applied above which both splendid sensitivity and specificity
are obtained. This makes absolutely sense, since not all variants within the viral
population are clinical relevant. The question that rises here again is what is the
clinical cut-offs that is needed to define minority drug-resistant variants. Within
Janssen Pharmaceuticals the 1% reporting limit was applied, but this can be low-
ered nowadays to 0.5% when applying VirVarSeq or even down to 0.4% when
applying ViVaMBC.
5.2 Valorization
HCV and HIV exist in infected patients as a large viral population of intrahost
variants, which may be differentially resistant against antiretroviral drugs. Hence,
standard antiretroviral therapy (ART) consists of a combination of drugs to maxi-
mally suppress the virus and stop the progression of the disease. The combination
of drugs depends on the constitution of the viral population of the infected pa-
tients. Therapeutic guidelines therefore recommend genotypic resistance testing
before initiating ART [123]. Currently, standard genotyping by Sanger sequenc-
ing [22] is used in clinical practice to detect the viral variants. However, Sanger
sequencing can only detect viral variants representing more than 15 to 25% of the
viral population. A common and clinically relevant question that clinicians ask
is: how often this genotyping underestimates the presence of low-frequency vari-
ants and whether these low-frequency variants can contribute to treatment failure.
Since more sensitive techniques have been developed, including massively paral-
lel sequencing, low-frequency variants can be detected and quantified nowadays
down to 0.5 to 1% [23]. However, clinical relevance of detecting low-frequency
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variants remain open to debate. According to some studies, low-frequency base-
line drug resistance is associated with a higher risk of treatment failure [14–16].
Other studies have not found an influence of minority resistance mutations on the
treatment response [21].
One of the reasons why this question remains open to debate might be the chal-
lenges involved during the variant calling. The technical noise that is interpreted
as a low-frequency variant might disturb the final analysis. Hence, algorithms
with high specificity in combination with a high sensitivity can help in defining
the clinical relevance of low-frequency variant detection. Existing methodologies,
LoFreq [47], V-phaser 2 [44], and ShoRAH [45] showed very high specificities but
tend to miss some important discoveries. The presented methodologies VirVarSeq
and ViVaMBC showed high sensitivities in combination with good specificities
when variants are reported down to 0.5%. Hence, application of these methods
can help in determining if a drug-resistant variant at 0.5% is still clinically rele-
vant.
Detection of resistance associated variants against anti(retro)viral drugs repre-
sents the economic finality of the project. Since these drugs target certain proteins,
consisting of amino acids translated from the viral genome, it is of interest to inves-
tigate variants at codon level. Most variant callers described in literature, however,
call the variants at the SNP level but here linkage information between the differ-
ent SNPs is lost. Therefor, we developed variant callers VirVarSeq and ViVaMBC
who call variants at the codon level. Hence the economic objective of the project
is immediately taken into account.
Currently at Janssen Pharmaceuticals the pipeline VirVarSeq, described in chap-
ter 3, is used to support some of their clinical trials to determine resistance asso-
ciated mutations. These mutations are put in the label of the drug which guides
the clinicians in determining the best combination therapy for each patient. Most
samples taken during the clinical trial are sequenced using Sanger. Only those
samples from patients that fail therapy and where no known resistance associated
mutations were found, are deep-sequenced and analyzed using our pipeline.
5.3 Perspectives
It is clear that massively parallel sequencing opens new routes to study viral diver-
sity and its impact on resistance. A big step forward in the use of these techniques
in clinical practice is the recent approval by FDA. End of 2013, FDA granted first
marketing authorization for Illumina’s MiSeqDX [132]. This recent authorization
of a sequencing platform for clinical use will probably expand the use and develop-
ment of genome-based tests [130, 131] and will promote the further development
of personalized medicines. However, MPS techniques and the variant calling tools
will not immediately substitute Sanger sequencing in routine clinical practice to
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personalize the combination treatment of HIV patients for instance. Before this is
going to happen, it is essential to perform large prospective studies to assess the im-
pact of low-frequency variants on virological response; clinical cut-offs need to be
defined for minority drug-resistant variants. As said, the developed tools can help
here since they have an increased sensitivity versus the existing methodologies.
Since Illumina’s MiSeq and MiSeqDx is based on the sequencing-by-synthesis
approach, similar to Illumina’s Genome Analyzer IIx, VirVarSeq and ViVaMBC
are expected to work with these technologies as well and hence, their potential can
be further exploited.
Illumina is currently the leader in the NGS industry which is of course good
news for the application domain of the developed methodologies. However, the
rapidly evolving field of MPS [133] is a challenge for the development of such
methodologies. To allow application of the developed variant callers to new emerg-
ing technologies, the variant callers should be sufficiently generic. Base-calling
itself is highly technology dependent, hence our variant callers start only after
base-calling and alignment of the reads. As long as the quality scores have an
interpretation of substitution error probabilities both methods can be applied and
their increased sensitivity versus the existing methodologies can be exploited. The
pyrosequencing techniques, like 454 [29] and Ion Torrent [134] are hence not ap-
propriate since the quality scores have an other interpretation. Currently, the single
molecule sequencing techniques are emerging. These technologies look promising
since they do not need the amplification steps prior to the sequencing and hence
an important source of error in the sequencing process can be avoided. The cur-
rent leader in this field is Pacific Biosiences with its single molecule real time
sequencing technique, also known as SMRT [128]. It is, similar to Illuminas
technology, a sequencing-by-synthesis technique based on the polymerase chain
reaction. Another single molecule sequencing technology is Nanopore sequenc-
ing. This technology is based on the transit of a DNA molecule through a pore
while the sequence is read out base by base through the effect on an electric cur-
rent or optical signal [135]. Contradictory, both methods suffer from rather high
error rates and further improvement will therefor be required especially when low-
frequency variants are of interest. Whether or not these technologies will shake
up the sequencing industry or if Illumina will remain the leading technology in
the coming years remains to be seen. However, we believe that our variant callers
have potential to be adapted to work for these emerging technologies as well.
Additionally, the application domain of VirVarSeq and ViVaMBC is not re-
stricted to virology which increases their potential. The increase in sensitivity to
detect low-frequency variants that these methods can offer, will be highly benefi-
cial across many fields. One example is within oncology, where there is a substan-
tial amount of variation within cancer types that affect specific tissues or organs
and that leads to different disease outcomes and responses to treatment. Massively
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parallel sequencing has emerged here as well as an excellent tool to characterize
the individual cancer types in order to better understand the underlying hetero-
geneity [124, 125]. The somatic point mutations which characterize the cancer
genome, occur however at low frequency [126]. Hence highly sensitive variant
callers need to be applied [127]. In this sense, a future direction could be to ex-
tensively test and fine tune ViVaMBC as a somatic mutation-calling method where
coverages are only a hundred up to thousand fold, which is a typical setting for
tumor data. These decreased coverages will imply that variants with frequencies
lower than 0.5% can not be detected with good specificity. The simulation exer-
cises in chapter 2 and 4, where the frequency estimates are investigated at different
coverage, may suggest that variants down to 2% or maybe 1% could be detectable.
But further investigation is needed.
5.4 Conclusion
Two variant calling tools, VirVarSeq and ViVaMBC are proposed for identifying
variants within viral populations using Illumina sequencing. They both call vari-
ants at the codon level to allow for an immediate biological interpretation in terms
of drug resistance variants. The way how they overcome the challenge of reducing
false-positive findings during variant calling differs and starts from two different
viewpoints. VirVarSeq is a quality-based filtering approach where codons below a
predefined quality are filtered out. The quality cutoff is defined as the intersection
point of two components from a mixture distribution fitted on the quality values of
the codons, which is defined as the minimum quality score of the three nucleotides.
This data-driven definition of the quality cutoff allows for differences in quality be-
tween runs. ViVaMBC, on the other hand, keeps all detected codons but models
the error probabilities of the base call and the second best base call by using the
quality scores of the individual nucleotides. Based on these error probabilities the
codons are divided into clusters where the major variant within the cluster defines
the actual variant and where the cluster size is an estimate of the variant frequency.
Comparison of the two methodologies shows that they have both a splendid
sensitivity while retaining very good specificities for variant frequencies above
0.5%. Above this limit, both methods report in general the same variants with
similar frequencies. However, scientists at Janssen Pharmaceuticals prefer the
VirVarSeq pipeline while statisticians are more in favor of ViVaMBC. Filtering
approaches are more imbedded in the field of bioinformatics although they are
sensitive to the parameter choices. This is partly overcome by applying an adap-
tive approach where the threshold is defined on each individual data set counting
for differences in quality between the runs. However, VirVarSeq still bears the
potential risk of biasing the results by removing parts of the data which does not
apply for ViVaMBC. Further, the number of reported variants below the report-
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ing limits are much lower for ViVaMBC. This would allow to report all variants
independent of reporting limits if some false-positive findings were allowed. On
the other hand, the performance characteristics of VirVarSeq are much better, both
in computing time as well as in development time and hence the more pragmatic
approach, VirVarSeq might be preferred especially in an industrial setting.
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Supplementary Material. Quality
Based Adaptive Filtering.
A.1 Sample preparation
The preparation of the HCV-NS3 plasmids as well as the HCV clinical samples
can be found in the material and methods section of chapter 2. The sequencing
protocols for Illumina and 454 are also described in this chapter.
A.2 Indel table
All reads containing indels are investigated in a separate analysis dedicated to dis-
cover rare codon insertions. The insertions and deletions that occur within these
reads are listed in a separate pileup table, referred to as indel table. It reports the
actual insertion or deletion and the number of times it was observed for each posi-
tion where an indel occurred. The frequency of the insertion is calculated using the
coverage at the previous position, the frequency of the deletion is calculated using
the coverage of the actual position. No filtering based on quality values is applied
on the indel table. Composing the indel table is performed in the codon_table.pl
script and the results are written in the sub-directory results/codon_table as a sep-
arate file.
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A.3 Model selection
Mixture distributions with different number of components were fitted on the min-
imum quality scores of the codons for 5 HCV samples, sequenced on 5 different
sequencing runs (Figure A.3). Each HCV sample is colored differently. The good-
ness of fit (GoF) was assessed using the Cramér-von Mises statistic [122] where
the probabilities from the fitted mixture distribution are compared to the empiri-
cal probabilities; the smaller this statistic, the better the fit. Mixture distributions
with 3 and 4 components show a better fit compared with a lower or higher num-
ber of components (Figure A.3a). Two hundred HCV samples were investigated
to decide between fitting a mixture distribution with 3 or 4 components (Figure
A.3a). The goodness of fit of these 2 models is comparable. Hence, we have cho-
sen to fit the more parsimonious mixture model with 3 components. Moreover, the
3 component model has a more straightforward biological interpretation: a point
probability around 2 to account for the data manipulation performed by Illumina,
an error distribution and a distribution of the reliable calls.
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Figure A.1: Coverageplot for NS3 region of a clinical HCV sample where the consensus
clearly deviates from the wild type. The coverage is plotted with dotted, dashed and full
line respectively after reference mapping, consensus mapping and Q-cpileup with QIT
equals 26. After consensus mapping the coverage improved especially in less conserved
regions of the virus. It is in these regions that the gain of iterative mapping is expected.
(see peak around codon position 45). During mapping more mismatches are allowed
compared to the default BWA setting. Currently the following parameters are used -n12
and -k6. Other settings might be more appropriate for other viruses. After applying
Q-cpileup a dip in coverage is observed in the GC-rich region which is known to be
error-prone and were a lot of false-positive findings are filtered out.
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Figure A.2: Comparative analysis of different summarizations of the quality scores of
codons. The quality scores need to be summarized at two stages. The quality scores of the
three nucleotides building up a codon are summarized by their mean or by their weakest
link, the minimum quality score of the three. The quality scores of identical codons at one
position of the reference genome are summarized by their mean or by the median in order
to get a quality measure in the final codon table. Each summarization is indicated with
another color and line type. In the legend the summarization of the quality scores of the
three nucleotides is stated first followed by the summarization of the quality scores of
identical codons at one position. It is clear that the weakest link to summarize the quality
scores of the three nucleotides gives the best separation between low and high quality
codons. To summarize the codons at one position the mean is chosen as to take outliers
into account.
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Figure A.3: a) Goodness of fit for mixture models with different number of components
ranging from 2 to 5 calculated for 5 different HCV samples. Each sample is colored
differently and has another plotting symbol. The fit with 3 or 4 components is the best
depending on the sample. b) Goodness of fit for mixture models with 3 components on the
x-axis and with 4 components on the y-axis for 200 HCV samples. The GoF is scattered
around the identity line. No overall clear distinction between the two fits can be made and
hence the one with the easiest biological interpretation is chosen, namely 3 components.
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Figure A.4: Investigation of the effect of the intra-run variability of the QIT’s on the
reported codon frequencies when trimming but no filtering is applied. a) Plot of the
number of variants with a frequency greater than 1% for each of the samples sequenced on
lane 1(x-axis) and lane 2 (y-axis). b) Boxplots of the differences in codon frequency
between the two lanes for each of the 42 samples. c) Comparison of all codon frequencies
on the log scale between the two lanes for the sample where the maximum frequency
difference is observed. The frequencies of codons not present in the other lane are plotted
in gray. d) Relative change for these codons where the absolute difference was maximal is
plotted for each sample and the sizes of the dots are scaled according to the estimated
frequency in lane 1. The relative change is calculated [x1-x2]/x2 with x1 and x2 the codon
frequencies for lane 1 and 2 respectively. The sample where the maximum difference was
observed is indicated in red.
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Figure A.5: Analysis of a HIV clinical sample a) Fit of mixture distribution with QIT
indicated by verticaldashed line. b) Boxplot of the major variants frequencies before and
after filtering based on QIT. By removing false positive variants, the major frequencies
move towards 100% c) Scatterplot of minor variants with the frequencies before filtering
on the X-axis and after Q-cpileup on the Y-axis. Again a reduction of false-positive
findings after filtering is observed although less pronounced as compared to HCV samples.
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Figure A.6: Analysis of HCV sample sequenced on HISeq. Fit of mixture distribution with
QIT indicated by dashed line which proves that the strategy as presented in chapter 3 can
be used on HiSeq data as well. The quality scores in Illumina are calibrated using a
quality table which is renewed each time a new chemistry is presented. Each time a few
points of difference can be expected, but the automated pipeline should incorporate most
of these. The points of differences observed are: The maximum quality score is 41 (while it
was 40 before) resulting in 40 intervals of equal width. The point probability at 2
disappears as well, but a new mode can be seen around quality score 7. The automated
pipeline checks if the first quantile of the total distribution is above 2. If not, a small initial
estimate of the variance is chosen to force a point probability to be fitted, otherwise the
same estimate for all three distributions is chosen.
B
Users Guide VirVarSeq
B.1 General descripton
VirVarSeq is a toolset designed to call variants at the codon level in viral popula-
tions from deep sequencing data. It is available, together with a users guide and
test data at:
http://sourceforge.net/projects/virtools/?source=directory.
The pipeline starts from short-read sequences and a reference genome. It reports a
codon table filtered based on the quality scores. A more detailed description along with the
options will follow. The toolset consists of several components:
1. Mapping versus Reference (map_vs_ref.pl). Variant inference in viral populations
starts by aligning the reads to a reference genome.
2. Determination of Consensus Sequence (consensus.pl). The reference genome may
contain bases that do not represent the majority of the reads. Based on the previous
alignment, the consensus at each position of the reference genome will be deter-
mined.
3. Mapping versus Consensus (map_vs_consensus.pl). The reads will be realigned
against the consensus sequence to increase coverage.
4. Q-cpileup. A codon table will be constructed where the number of false-positive
findings is reduced by exploiting the quality scores of the nucleotides. The method
is adaptive to allow differences in qualities between the runs. It consists out of three
consecutive analysis steps.
(a) Retrieve the quality of codons (codon_table.pl)
(b) Determine Q-intersection threshold (mixture_model.pl)
(c) Filtering and reporting of codon table (mixture_model.pl)
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B.2 Prerequisites
• BWA. BWA is a software package used for mapping of short-read sequences against
a reference genome or the consensus sequence calculated in the pipeline. It is avail-
able at: http://bio-bwa.sourceforge.net/. VirVarSeq is recently tested with version
0.7.5a.
• R. R is a software environment for statistical computing used by Q-cpileup. It is
available at: http://www.r-project.org/. The R-package rmgt is embedded in the
pipeline. It is an R-wrapper to run the original Fortran code of McLachlan described
in Biometrics [60] which fits truncated mixture models. The R-package is also used
to produce some diagnostic plots to judge if chosen thresholds are acceptable and/or
interpretable (more details in corresponding chapter 3). VirVarSeq is recently tested
with version 3.0.1.
• Fortran. A fortran compiler is necessary to be able to run the R-package rmgt. A
compiler can be downloaded from http://gcc.gnu.org/fortran/.
• Perl. Perl is a high-level, general-purpose, interpreted, dynamic programming lan-
guage. It is available at: http://www.perl.org/. VirVarSeq is recently tested with
version v5.10.1.
• Perl modules. The Perl module "Statistics::Basic" is used by VirVarSeq
B.3 Download
https://sourceforge.net/projects/virtools/
B.4 Getting started
1. Download VirVar.tar.gz. (see above)
2. Unzip VirVar.tar.gz.
tar xvfz VirVarSeq.tar.gz
3. Install the R package "rmgt" (included in the distribution file VirVar.tar.gz). Within
R use the following:
install.packages("rmgt_0.9.001.tar.gz",repos=NULL,lib="lib")
4. Set environment variables so the VirVar Perl and R modules are found.
export PERL5LIB=/home/ec2-user/VirVar/lib
export R_LIBS_USER=/home/ec2-user/VirVar/R/lib
5. Test installation.
./run.sh
The run.sh script creates a log file (VirVarSeq.log) where you can follow the progress.
6. Results. The output of the run.sh script is stored in directory<VirVar>/testdata/results
The subdirectories are:
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• <VirVar>/testdata/results/map_vs_ref
• <VirVar>/testdata/results/consensus
• <VirVar>/testdata/results/map_vs_consensus
• <VirVar>/testdata/results/codon_table
• <VirVar>/testdata/results/mixture_model
B.5 Usage
The VirVar pipeline makes use of a run.sh file.
User must specify:
• indir : directory where the fastq.gz files of the different samples to be processed are
stored.
• outdir : directory where the output needs to be saved.
• samples : txt file with the names of the samples that need to be processed. The
names are the first part of the fastq names created by Illumina. Multiple samples can
be processed sequentially by having multiple sample names in the samples file.
• ref : path directing to the reference fasta file.
• startpos : position of the reference (at nucleotide level) where the determination of
the consensus needs to start.
• endpos : position of the reference (at nucleotide level) where the consensus determi-
nation ends.
• region_start : position of the reference (at nucleotide level) where the pileup of the
codons needs to start. This position is equal or higher to startpos.
• region_len : number of codon positions that need to be covered in the pileup table.
Region_len 3 defines the length (at nucleotide level) on the reference genome that
is reported in the pileup table.
• qv : a quality score used for filtering of the codon table. When applying Q-cpileup as
described in chapter 3, Qv should be set to zero. The quality score used for filtering
will be derived data driven. The option is left to specify a qv upfront. In this last
case there is no need to run mixture_model.pl.
• trimming : If trimming is 0, soft-clipping as defined by the aligner will be ignored.
If trimming is 1 (default), reads will be soft-clipped prior to the analysis.
B.6 FAQ
1. got message "Can‘t locate File.pm in @INC" running map_vs_ref.pl Please point
the PERL5LIB environment variable to the <VirVar>/lib directory where the Perl
libraries are installed
2. How can I install the Statistics::Basic Perl module? Perl modules can be installed
using cpan. This installer will also install all dependend packages.
cpan -i Statistics::Basic
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3. I don‘t have cpan, how can I install the Statistics::Basic Perl module? You must first
install the cpan tool in order to install other Perl modules. Beware you must have
root (or sudo rights) to install cpan tool.
sudo yum install cpan
B.7 Description test data
The test data provided together with the code, are 2 random samples containing 25% of the
reads of a mixture of HCV plasmids (mixed 1:100). These mixtures of HCV plasmids are
described in chapter 3 to assess the filtering accuracy of Q-cpileup, one of the components
in the pipeline. Two different HCV plasmids were used for the mixture, each comprising
the viral NS3-4A fragment. Site-directed mutations have been introduced into the con1b
replicon plasmid pFK_i341_PI Luc_NS3-3’_ET (wild type) as described earlier [91, 92].
These plasmids, wild type and mutant, differ only in two codons (5 single nucleotides), as
confirmed by Sanger sequencing. The HCV plasmid carrying the mutations is mixed into
the wild type HCV plasmid at different proportions (1:10, 1:50, 1:100, 1:200). Following
manufacturing protocols, the mixtures together with the WT and mutant are paired-end
sequenced on Illumina GAIIx using 147 cycles. The fastq data from the 6 different samples
can be downloaded from the European Nucleotide Archive, accession number PRJEB5028.
The reference genome used is hepatitis C virus type1b complete genome, isolate Con1
with GenBank ID AJ238799.1 which can be downloaded from:
http://www.ncbi.nlm.nih.gov/nuccore/AJ238799
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Supplementary Information: Model
Based Clustering
C.1 Sample preparation
The preparation of the HCV-NS3 plasmids as well as the HCV clinical samples can be found
in the material and methods section of chapter 2. The sequencing protocols for Illumina and
454 are also described in this chapter 2.
C.2 Workflow
1. Off-line base calling with the option of second best base call:
bustard.py --CIF <directory with intensities> --make --with
-second-call --with-qseq --keep-dif-files
2. Demultiplex:
configureBclToFastq.pl --input-dir <input directory>
--output-dir <output directory>
3. Alignment with for instance BWA, creating a sam file
4. Convert second best base qseq files to fastq with fastqconverter from Casava:
FastqConverter --in <inputfile> --out <outfile>
5. Add second best base call to sam, E2 and U2 tags are standard foreseen in sam to be
filled by second best base calls and there quality scores: own Perl script submitted at
sourceforge [http://sourceforge.net/p/vivambc/code/ci/master/tree/]
6. Convert sam to sorted bam with samtools:
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samtools view -b -t <fasta of reference> <input sam file> |
samtools sort - <name of output>
7. Create heading with picard in order to be able to perform the next step:
java -jar /opt/picard-tools-1.86/AddOrReplaceReadGroups.jar
I=<inputfile> O=<outputfile> LB=none PL=illumina PU=none
SM=none
8. Change bam positions using clipreads of GATK:
java -jar /opt/GenomeAnalysisTK-2.3-9/GenomeAnalysisTK.jar -T
ClipReads -I <input bam file> -o <output bam file > -R <input
ref file> -CR HARDCLIP\_BASES
9. Run R-script to perform model based clustering
C.3 R-code
The R-code together with the perl scripts are available under code at:
http://sourceforge.net/p/vivambc/code/ci/master/tree/
The R-code is parallelized which makes it possible to run each codon position on a
separate core in order to speed up. The following command can be used:
mpirun -np <number of nodes> Rscript ViVaMBC.R.
The output is a codonTable.txt file where the position, the codons and their frequencies
are reported. The code is tested on Amazon Web Services (AWS). For a region covering
181 windows the code runs for approximately 12 hours when a server with 16 cores and
60GB of RAM is used. Without parallelization it would take more than 7 days to obtain the
results. Further optimalization of the R-code is most probably possible.
C.4 Error correction by second best base calling
The amount of errors that could be corrected by second best base calls is determined using
the mixture of plasmids. These mixtures have two variant positions, position 36 (GTC
(consensus) → ATG) and 155 (CGG (consensus) → AAA). All codons that are different
from the two possible codons at each variant position are considered as error. For each false
positive we check where the error occurs; which nucleotide or nucleotides within the codon
differs from the ones in the true codons. In the next step, it is tested if the replacement of the
error by the second best base call delivers one of the true codons. This procedure is repeated
for the 4 mixing proportions, 1:200, 1:100, 1:50, and 1:10. In total 70% of the errors could
be corrected by the second best base call (Figure C.1). The individual percentages for each
codon position and each mixing proportion is shown in Table C.1.
C.5 Pileup
The results of ViVaMBC are compared with the codons present in the raw data after trim-
ming (Table 2, chapter 4). The trimming is done by removing all bases, soft clipped by the
alignment tool which is indicated in the CIGAR with S. These bases are most likely errors
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Correction by Second Best Base Calls
Errors
Corrected
Figure C.1: Error correction by second best base calls. Pie charts where the total pie
represents the number of errors observed. 70% of them could be corrected by the second
best base call, while the other 30% remain error.
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Pos 1:200 1:100 1:50 1:10
36 72.5 69.6 71.0 68.2
155 73.1 73.1 72.5 65.6
Table C.1: Percentage of errors that could be corrected by second best base calls for each
variant position and for each mixing proportion.
since no translocations or big deletions are expected in the NS3 region. After trimming,
all codons present in the data will be tabulated for each codon position. In chapter 4 this
approach will be called pileup (in analogy with mpileup of samtools).
C.6 ViVaMBC at the SNP level
ViVaMBC has been optimized for m = 3 to retain linkage information between single nu-
cleotide polymorphism, which allows for an immediate biological interpretation. Nonethe-
less, the algorithm can be applied with different window sizes m.
We have run ViVaMBC with window size m = 1 to call SNPs on the mixture of plas-
mids, in analogy with the existing methods. The estimated frequencies of the 5 known
SNPs are reported in Table C.2. All variants could be retrieved with frequencies close to the
mixing proportions. All other variants, besides the 5 SNPs, are assumed to be false-positive
findings. ViVaMBC at the SNP level reports more false-positive findings compared with the
existing methodologies similar to ViVaMBC at codon level (Table C.2). However, their fre-
quencies remain well below 0.35%. Only one outlier was observed at a frequency of 0.65%
for the mixing proportion 1:100. (Figure C.2). Overall ViVaMBC has a higher sensitivity
and specificity for the discovery of SNPs down to a frequency of 0.5% in comparison with
the other methods.
ViVaMBC
SNP (WT) 1:200 1:100 1:50
36 A (G) 0.49 0.93 2.23
T (T)
G (C) 0.43 0.88 2.18
155 A (C) 0.49 0.89 2.15
A (G) 0.45 0.89 2.20
A (G) 0.43 0.87 2.14
Number of false SNPs 132 139 209
Max Freq of false SNPs 0.32 0.65 0.34
Table C.2: Sensitivity and specificity of ViVaMBC at the SNP level. Frequency estimates of
the true SNPs are close to the mixing proportions for all 3 mixes under investigation
(1:200, 1:100 and 1:50). The bottom rows of the table report the total number of false
SNPs over the whole NS3 region (543 bp long) together with their maximum frequency.
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Figure C.2: ViVaMBC at SNP level Boxplots of the frequencies of all minor variants
discovered in the three mixtures 1:200, 1:100 and 1:50 are plotted for ViVaMBC at SNP
level. The true positives are indicated with gray crosses.
C-6 APPENDIX C
C.7 Contribution of second best base calls
ViVaMBC clusters variants based on the error probabilities of both the first and the sec-
ond best base call. These second best base calls must be retrieved during base-calling.
However, in some cases these second best base calls might be difficult to get, for instance
sequencing providers perform often RTA and provide the best base calls only. Therefore,
the performance of ViVaMBC is checked if only the best base calls are available. Equation
3 simplifies than to a simple logit model where c equals r instead of a multinomial logit
model. Sensitivity and specificity is again investigated using the mixture of plasmids. The
results are displayed in Table C.3. The estimated frequencies of the two real variants are
close to the mixing proportions for the four different mixes. The number of reported vari-
ants over the whole NS3 region is displayed in the fourth column of Table C.3 together with
the maximum frequency of the false-positive findings among the reported codons. For the
plasmid mixtures, each codon differing from the wild type other than the spiked-in variant
is considered to be an error. Hence, exclusion of second best base calls seems to have an
increase in the specificity of the method without losing the sensitivity. However, some of
the sequence differences at low-frequencies are expected to be real as they might originate
from errors introduced during plasmid preparation. Hence, the increase in specificity is
most probably a trade-off with the sensitivity for the very low-frequency variants.
Additionally, the influence of coverage depth on the accuracy of the frequency esti-
mates is investigated using the plasmid data, mixed 1:200, at codon position 155. A similar
experimental setup was performed as described chapter 4. The frequencies of the variants
for this position for each of the 90 re-sampled datasets are plotted in Additional Figure C.3.
The true codon variant AAA (green dots) was detected in all datasets. Averages frequency
estimates over the 10 repeats are indicated with green triangles. The frequency estimate
based on the error probabilities of best and second best base calls on the full dataset is
indicated with a horizontal dashed line. In general, the frequency estimates are slightly
underestimated. The number of false-positive findings is again much lower in comparison
with ViVaMBC where the error probabilities of the second best base calls are taken into
account. Although this might hint to an increased specificity, it is possible that it actually
implies a decreased sensitivity as suggested above.
To investigate this further the method is applied on the GC-rich region of the clinical
HCV sample used in chapter 4. The ViVaMBC results with and without second best base
calls are plotted on the y- and x-axis respectively in Figure C.4. Codons that are exclusively
reported with one of the methods are displayed in gray on the corresponding axis. The vari-
ants that were not present after 454 sequencing are displayed with triangles. Above 0.5% the
two methods are in agreement, with slightly lower frequency estimates when omitting the
second best base calls. Further, inclusion of the second best base calls in the model based
clustering reveals more variants (similar to the results of the HCV plasmid) and sixteen of
them are reported with the 454 experiment with frequencies up to 0.3%. Note, that the num-
ber of missed discoveries is probably higher since the 454 experiment was not sequenced
deep enough to reveal frequencies below 0.05%. This suggests that some sensitivity is lost
when second best base calls are omitted. However, both ViVaMBC implementations give
very similar results when a reporting limit of 0.5% is applied.
C.8 Supplementary figures
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Mixing Prop 36 ATG (%) 155 AAA (%) N◦ Codons max noise freq (%)
1:200 0.44 0.40 289 0.52
1:100 0.89 0.84 291 0.51
1:50 2.20 2.16 301 0.57
1:10 10.82 9.89 253 0.38
Table C.3: Sensitivity and specificity of ViVaMBC in plasmid experiment when only the
error probabilities of the best base calls are incorporated in the model. The estimated
frequencies of the variants at codon position 36 and 155 for the four different mixing
proportions are displayed together with the number of reported codons and the maximum
frequency of the false-positive findings among them.
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Figure C.3: Influence of coverage depth on the estimation of τj when ViVaMBC is solely
based on the error probabilities of the best base calls. Datasets with lower coverages are
generated by random sampling a fraction (f=0.1, 0.2, . . . , 0.8 ,0.9) of the reads from the
original dataset. Ten datasets were generated for each fraction f resulting in 90 datasets.
The reported variants for all re-sampled datasets were plotted and colored according to
the discovered codon. The green dots indicate the true variant and the few others are
false-positive findings. The average frequency of the true variant (averaged over the ten
random samples) is indicated with triangles. The dotted line is the true frequency as
estimated from the original dataset when the error probabilities of the second best base
calls are taken into account.
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Figure C.4: Impact of the second best base call error probability on ViVaMBC. The
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Figure C.5: Frequency distribution of the false-positive findings for the 4 mixing
proportions after pileup and ViVaMBC. The raw data include some error induced variants
with frequencies above 0.5% and even 1% which will hamper the discovery of the true
low-frequency variants at position 36 and 155 (black boxplots). After applying ViVaMBC
the frequencies of these false-positive findings only reach 0.25% (gray boxplots).

D
Curriculum Vitae
D.1 Experience
• Principal Biostatistician, Janssen Pharmaceuticals, april 2014 - Present.
– Give statistical support to the discovery teams, with the main focus on oncol-
ogy projects.
• PhD-student, Baekeland mandatory, Ghent University and Janssen Pharmaceuticals,
2011-2014.
– Develop statistical algorithms for the detection of low-frequency variants within
viral populations using Illumina sequencing technology which is presented in
this thesis.
– Data mining of three multi-dimensional data sources that are used through-
out the drug discovery process to guide medicinal chemists: biological assay
data, chemical structure information and transcriptomics. In this project, un-
derstanding the chemistry is key to be able to bridge the different data sources.
(QSTAR: http://www.qstar-consortium.org)
• Scientific collaborator at Ghent University, 2010.
– qPCR data analysis: Multiple imputation of missing data in housekeeping
genes to allow a proper normalization of the data. Project in collaboration
with University Hospital Gent.
• Post-doctoral scientist at Janssen Pharmaceuticals, 2005-2008.
– Design, synthesis and validation of new biological active compounds within a
therapeutic area in order to identify new entities for clinical evaluation.
– Hit discovery by multivariate data analysis of biological assay data.
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D.2 Education
• PhD Statistical Data Analysis (IWT Baekeland grant), Ghent University, 2011-present.
Dissertation: Low-Frequency Variant Detection in Viral Populations using Massively
Parallel Sequencing Data.
• Master of Statistical Data Analysis, Ghent university, 2008-2010. Dissertation: Che-
mosensitivity prediction by gene profiling: targeting biological relevance.
• PhD Medicinal Chemistry (IWT Scolarship), Catholic University Leuven, 2001-
2005. Dissertation: Design and synthesis of potential β-turn mimetics: application
in peptide chemistry and in the development of small molecules.
• Master of Chemistry, Catholic University Leuven, 1999-2001.
• Bachelor of Chemistry, Catholic University Leuven, 1997-1999.
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